FOR OFFICIAL USE ONLY 54166

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

SEARCH REQUEST FORM

Examiner # (Mandatory): 73510 Requester's Full Name: Chris Tate

Art Unit 1651 Location (Bldg/Room#): 11 B09 Phone (circle) 305 306 308) 7114

Serial Number: 09/890,416 Results Format Preferred (circle): PAPER DISK E-MAIL

Title of Invention

Inventors (please provide full names): Drugs, foods, oral comps containing stilbene-type compounds

Earliest Priority Date: 1/29/99

Keywords (include any known synonyms registry numbers, explanation of initialisms):

RECEIVED
NOV 1 2001
(STIC)

Search Topic:

Please write detailed statement of the search topic, and the concept of the invention. Describe as specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples of relevant citations, authors, etc., if known. You may include a copy of the abstract and the broadcast or most relevant claim(s).

Please search the compound of claim 1 attached for treating bone loss (eg. osteoporosis) or for treating hypertension, especially-

-Thanks

STAFF USE ONLY

Searcher: Shaporia

Searcher Phone #: 308-4499

Searcher Location:

Date Picked Up:

Date Completed: 11/16/01

Clerical Prep Time:

Terminal Time:

Number of Databases:

Type of Search

_____ N.A. Sequence
_____ A.A. Sequence
_____ Structure (#)
_____ Bibliographic
_____ Litigation1
_____ Fulltext
_____ Procurement
_____ Other

Vendors (include cost where applicable)

_____ STN
_____ Questel/Orbit
_____ Lexis/Nexis
_____ WWW/Internet
_____ In-house sequence systems (list)
_____ Dialog
_____ Dr. Link
_____ Westlaw
_____ Other (specify)

PTO-1590 (2-99)

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 09:50:53 ON 19 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1947 - 19 Nov 2001  VOL 135 ISS 22
FILE LAST UPDATED: 18 Nov 2001  (20011118/ED)
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

```
=>

=>

=> d stat que l15
L1                  STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE
L7         65281 SEA FILE=REGISTRY SSS FUL L1
L11        40827 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7
L12           99 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11(L)(BONE(2A)(LOSS OR
                 RESORP?) OR ?OSTEOPO? OR ?HYPERTENS? OR (BLD OR BLOOD)(W)PRESSU
                 RE)
L14          978 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7(L)(?MEDIC? OR ?PHARM? OR
                 ?DRUG? OR ?THERP?)
```

L15 10 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND L12

=> d ibib abs hitrn l15 1-10

L15 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:555210 HCAPLUS
DOCUMENT NUMBER: 135:142233
TITLE: Pharmaceutical compositions containing estrogen agonist/antagonist and statins for treatment of osteoporosis and/or for lowering blood cholesterol
INVENTOR(S): Day, Wesley Warren; Lee, Andrew George; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 32 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001206845	A2	20010731	JP 2001-15626	20010124
EP 1123717	A2	20010816	EP 2001-1300527	20010122

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 2000-188923 P 20000126
US 2000-205327 P 20000421

OTHER SOURCE(S): MARPAT 135:142233

AB The invention provides a compn. contg. an estrogen agonist/antagonist, and a statin deriv for treatment of osteoporosis and/or for lowering blood cholesterol. The antiosteoporotic effect of (-)-cis-6-phenyl-5-[4-(2-pyrrolidine-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol (PPTN) in ovary-excised rats were examd.

IT **10540-29-1**, Tamoxifen **68047-06-3**, 4-Hydroxytamoxifen **89778-26-7**, Toremifene **116057-75-1**, Idoxifene **155701-61-4**, GW5638 **195611-82-6**, GW7604
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**pharmaceutical** compns. contg. estrogen agonist/antagonist and statins for treatment of **osteoporosis** and/or for lowering blood cholesterol)

L15 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:541600 HCAPLUS
DOCUMENT NUMBER: 135:117261
TITLE: Method using estrogen agonists/antagonists for reducing morbidity and the risk of mortality from cardiovascular disease, breast cancer, and osteoporosis
INVENTOR(S): Day, Wesley Warren; Lee, Andrew George; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1118323	A2	20010725	EP 2001-1300159	20010109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001226265	A2	20010821	JP 2001-5300	20010112

PRIORITY APPLN. INFO.: US 2000-175663 P 20000112
OTHER SOURCE(S): MARPAT 135:117261

AB The invention discloses methods, pharmaceutical compns., and kits useful in reducing cardiovascular morbidity and the risk of mortality in men and post-menopausal women and morbidity and the risk of mortality in post-menopausal women from the combined redn. of breast cancer, osteoporosis and cardiovascular disease by the administration of estrogen agonists/antagonists. The compns. are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier, or diluent. The compns. and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects assocd. with estrogen administration.

IT **82413-20-5 82413-20-5D**, isomers, N-oxides, esters, and **prodrug** derivs. **83647-31-8 83647-31-8D**, isomers, N-oxides, esters, and **prodrug** derivs. **83647-33-0 83647-33-0D**, isomers, N-oxides, esters, and **prodrug** derivs. **83647-34-1 83647-34-1D**, isomers, N-oxides, esters, and **prodrug** derivs. **103199-13-9 103199-13-9D**, isomers, N-oxides, esters, and **prodrug** derivs. **170928-99-1 170928-99-1D**, isomers, N-oxides, esters, and **prodrug** derivs.
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen agonists/antagonists for reducing morbidity and risk of mortality from cardiovascular disease, breast cancer, and **osteoporosis**)

L15 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER:	1999:778967 HCAPLUS
DOCUMENT NUMBER:	132:231295
TITLE:	Selective oestrogen receptor modulation: molecular pharmacology for the millennium
AUTHOR(S):	Levenson, A. S.; Jordan, V. C.
CORPORATE SOURCE:	Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL, 60611, USA
SOURCE:	Eur. J. Cancer (1999), 35(12), 1628-1639 CODEN: EJCAEL; ISSN: 0959-8049
PUBLISHER:	Elsevier Science Ltd.
DOCUMENT TYPE:	Journal; General Review
LANGUAGE:	English

AB A review with 34 refs. Knowledge of the mechanism of action and pharmacol. of tamoxifen and raloxifene, for the prevention of breast cancer and osteoporosis resp., has opened the door for the discovery of multifunctional medicines. There is now the potential to prevent osteoporosis, coronary heart disease, breast and endometrial cancer in postmenopausal women with elevated risk factors.

IT **10540-29-1**, Tamoxifen
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective estrogen receptor modulation and mol. **pharmacol.** in relation to breast cancer treatment and **osteoporosis**

prevention and treatment in postmenopausal women)
REFERENCE COUNT: 135
REFERENCE(S):
(1) Aronica, S; Mol Endocrinol 1993, V7, P743 HCAPLUS
(2) Assikis, V; Eur J Cancer 1996, V32A, P1464 HCAPLUS
(4) Beato, M; Endocrine Rev 1996, V17, P587 HCAPLUS
(6) Belleau, B; J Med Chem 1964, V7, P776 HCAPLUS
(7) Berry, M; EMBO J 1990, V9, P2811 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:9719 HCAPLUS
DOCUMENT NUMBER: 130:61616
TITLE: A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
INVENTOR(S): Dietrich, John; Ljunghall, Sverker; Sjogren, Sven
PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857656	A1	19981223	WO 1998-SE1095	19980608
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9879458	A1	19990104	AU 1998-79458	19980608
ZA 9804947	A	19990104	ZA 1998-4947	19980608
EP 1001802	A1	20000524	EP 1998-929965	19980608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6284730	B1	20010904	US 1998-125247	19980814

PRIORITY APPLN. INFO.: SE 1997-2401 A 19970619
WO 1998-SE1095 W 19980608

AB The invention relates to a combined pharmaceutical prepn. comprising parathyroid hormone and a bone resorption inhibitor, said prepn. being adapted for (a) the administration of parathyroid hormone (PTH) during a period of approx. 6 to 24 mo; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approx. 12 to 36 mo. An example was given showing an enhanced effect on bone mineral d. with sequential administration of PTH and the bisphosphonate alendronate.

IT **10540-29-1**, Tamoxifen **82413-20-5**, Droloxifene
89778-26-7, Toremifene **116057-75-1**, Idoxifene
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen modulator; combined **pharmaceutical** prepn. comprising parathyroid hormone and a **bone resorption** inhibitor)

REFERENCE COUNT: 3
REFERENCE(S):
(1) Flora, L; US 4822609 A 1989 HCAPLUS

(2) Pfizer Inc; EP 0792639 A1 1997 HCAPLUS
(3) Steven, W; US 5118667 A 1992 HCAPLUS

L15 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:589150 HCAPLUS
DOCUMENT NUMBER: 127:239133
TITLE: Pharmaceutical compositions containing combination of droloxifene and progestins for the treatment of osteoporosis
INVENTOR(S): Maclean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 791356	A1	19970827	EP 1997-301173	19970221
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09315977	A2	19971209	JP 1997-39073	19970224
CA 2198574	AA	19970828	CA 1997-2198574	19970226
AU 9714967	A1	19970904	AU 1997-14967	19970227
AU 712656	B2	19991111		
ZA 9701718	A	19980827	ZA 1997-1718	19970227
US 6057309	A	20000502	US 1998-193265	19981116

PRIORITY APPLN. INFO.: US 1996-12400 P 19960228
US 1997-803710 B1 19970221

OTHER SOURCE(S): MARPAT 127:239133
AB Pharmaceutical compns. comprising an effective amt. of droloxifene (Markush structure given) or a pharmaceutically acceptable salt thereof together with a progestin are useful for inhibiting bone loss. Tablets contg. the above active ingredients 0.25-100, microcryst. cellulose 200-650, silicon dioxide 10-650, and stearic acid 5-15 mg each were prepd. The efficacy of the combination in treatment of a model of post-menopausal osteoporosis in rats is shown.
IT **82413-20-5 97752-20-0**, Droloxifene citrate
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**pharmaceutical** compns. contg. combination of droloxifene and progestins for treatment of **osteoporosis**)

L15 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1996:763169 HCAPLUS
DOCUMENT NUMBER: 126:42532
TITLE: Pharmacodynamic observation of ipriflavone as a bone resorption inhibitor
AUTHOR(S): Wu, Jingsheng; Liu, Zheng; Xue, Shuying; Chen, Siwei; Wang, Minwei
CORPORATE SOURCE: Dep. of Pharmacology, Shenyang Pharmaceutical Univ., Shenyang, 110015, Peop. Rep. China
SOURCE: Zhongguo Yiyao Gongye Zazhi (1996), 27(7), 307-310
CODEN: ZYGZEA; ISSN: 1001-8255
PUBLISHER: Zhongguo Yiyao Gongye Zazhi Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB Ipriflavone increased the bone d. that was decreased by prednisolone and

the capability of femoral bone against mechanic collision. It also increased serum phosphorus and calcitonin levels in combination with diethylstilbestrol.

IT **56-53-1**, Diethylstilbestrol
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**pharmacodynamic** observation of ipriflavone as a **bone resorption** inhibitor)

L15 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1996:483293 HCAPLUS
DOCUMENT NUMBER: 125:158592
TITLE: Zinc-calcium interaction in heparin-induced osteoporotic rabbit plasma
AUTHOR(S): Turan, B.; Delibasi, E.; Sinav, B.; Akkas, N.
CORPORATE SOURCE: Fac. Med., Ankara Univ., Ankara, 06100, Turk.
SOURCE: Trace Elem. Electrolytes (1996), 13(3), 138-142
CODEN: TEELEO; ISSN: 0946-2104
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Heparin (Liquemin) i.p. (1000 IU/kg/day) was administered to rabbits for 8 wk (group A). Animals of group B were injected calcitonin (100 IU/kg/day) in addn. to heparin (1000 IU/kg/day). Animals in group C were medicated like group B and 2 mg/kg/day tamoxifen (Nolvadex) was orally added to their diet. Heparin (A) and heparin + calcitonin (B) treatment caused an increase and a decrease in the blood plasma Ca and Zn levels, resp., whereas addnl. tamoxifen (C) treatment did not alter the Ca level, but the Zn level was still lower than the control. Plasma mineral contents (Na, K, Cl) except P decreased. The estrogen and globulin levels in blood serum increased, whereas the serum albumin and alk. phosphatase levels decreased. Some alterations in plasma biochem. parameters of heparin-induced osteoporotic animals were obsd. and some of these alterations were reversed by tamoxifen treatment.

IT **10540-29-1**, Tamoxifen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(zinc-calcium interaction in heparin-induced **osteoporosis** response to therapeutic **drugs**)

L15 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1984:132789 HCAPLUS
DOCUMENT NUMBER: 100:132789
TITLE: Clomiphene protects against osteoporosis in the mature ovariectomized rat
AUTHOR(S): Beall, Paula T.; Misra, Lalith K.; Young, Ronald L.; Spjut, Harlan J.; Evans, Harlan J.; LeBlanc, Adrian
CORPORATE SOURCE: Dep. Physiol., Baylor Coll. Med., Houston, TX, 77030, USA
SOURCE: Calcif. Tissue Int. (1984), 36(1), 123-5
CODEN: CTINDZ; ISSN: 0171-967X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Clomid (clomiphene citrate) [**50-41-9**], a mixed estrogen agonist-antagonist, protects mature ovariectomized breeder rats from changes in total body Ca and from deterioration of femur structure. Over 6 mo, mature ovariectomized rats took up Ca at the rate of 0.7 mg/day, whereas normal controls gained 2.5 mg/day. Injections of clomiphene kept ovariectomized rats in pos. Ca balance at 2.0 mg/day. Redns. in total femur Ca content, cortical thickness, and visible trabeculae of femurs in ovariectomized animals were prevented by chronic clomiphene

administration. This suggested a possible new line of investigation of the use of antiestrogenic **drugs** as therapeutic agents for hormone-dependent **osteoporosis** in animals and humans.

IT **50-41-9**
RL: BIOL (Biological study)
(**osteoporosis** inhibition by, after ovariectomy, calcium metab. in relation to)

L15 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1980:561250 HCAPLUS
DOCUMENT NUMBER: 93:161250
TITLE: Effect of an anion transport inhibitor on blood-brain barrier lesions during acute hypertension. Possible prevention of transendothelial vesicular transport
AUTHOR(S): Hardebo, Jan Erik; Johansson, Barbro B.
CORPORATE SOURCE: Dep. Histol. Neurol., Univ. Lund, Lund, S-223 62, Swed.
SOURCE: Acta Neuropathol. (1980), 51(1), 33-8
CODEN: ANPTAL; ISSN: 0001-6322
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB SITS (I) [**51023-76-8**] prevented leakage across the blood-brain barrier (BBB) into the brain parenchyma following a **hypertensive** insult induced by a local increase of the intraluminal pressure in anesthetized rats and by i.v. administration of adrenaline or bicuculline in conscious unrestrained animals. Since SITS increased cerebral blood flow the protection cannot be explained by a constrictor action on the cerebral vessels. SITS is a **drug** with complex action on the cell membrane including an inhibitory effect on anion transport mechanisms and on some cyclic AMP-mediated processes. It is possible that the protection of the BBB obsd. in the present study is related to a decrease in cyclic AMP, but a membrane-stabilizing effect can at present not be excluded.

IT **51023-76-8**
RL: BIOL (Biological study)
(blood-brain barrier lesions during acute **hypertension** prevention by)

L15 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1980:437284 HCAPLUS
DOCUMENT NUMBER: 93:37284
TITLE: Longistyline C, antibiotic isolated from Lonchocarpus longistyllus. Preliminary results of its pharmacological properties
AUTHOR(S): Cotias, Claudio Tenorio; Francisco de Mello, Jose; Pinto, Karline de Valesio; Goncalves de Lima, Oswaldo

CORPORATE SOURCE: Inst. Antibiot., Recife, Brazil
SOURCE: Rev. Quim. Ind. (Rio de Janeiro) (1979), 48(564), 12-15
CODEN: RQIRAI; ISSN: 0370-694X
DOCUMENT TYPE: Journal
LANGUAGE: Portuguese
GI



I

AB Longistylin C (I) [**64125-60-6**] appeared to have no significant effects on the parameters tested (**blood pressure**, cardiac frequency, smooth muscle, analgesia, inflammation, etc.) in lab. animals.

IT **64125-60-6**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**pharmacol.** of)

=> select hit rn l15 1-10
E1 THROUGH E17 ASSIGNED

=> fil reg
FILE 'REGISTRY' ENTERED AT 09:52:47 ON 19 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 17 NOV 2001 HIGHEST RN 370839-11-5
DICTIONARY FILE UPDATES: 17 NOV 2001 HIGHEST RN 370839-11-5

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
=>
=> d his l16

(FILE 'HCAPLUS' ENTERED AT 09:50:53 ON 19 NOV 2001)

SELECT HIT RN L15 1-10

FILE 'REGISTRY' ENTERED AT 09:52:47 ON 19 NOV 2001
L16 17 S E1-E17

=>
=>

=> d ide can l16 tot

L16 ANSWER 1 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **195611-82-6** REGISTRY
CN 2-Propenoic acid, 3-[4-[(1E)-1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Propenoic acid, 3-[4-[1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenyl]-, (E,E)-
OTHER NAMES:
CN GW 7604
FS STEREOSEARCH
MF C25 H22 O3
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, TOXLIT

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:235901

REFERENCE 2: 135:142233

REFERENCE 3: 134:290091

REFERENCE 4: 132:59356

REFERENCE 5: 132:58844

REFERENCE 6: 130:163193

REFERENCE 7: 127:243213

L16 ANSWER 2 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **170928-99-1** REGISTRY
CN Phenol, 3-[(1E)-1-[4-[2-[ethyl(phenylmethyl)amino]ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 3-[1-[4-[2-[ethyl(phenylmethyl)amino]ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-
FS STEREOSEARCH
MF C33 H35 N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:117261

REFERENCE 2: 132:102844

REFERENCE 3: 129:23441

REFERENCE 4: 123:330040

L16 ANSWER 3 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **155701-61-4** REGISTRY
CN 2-Propenoic acid, 3-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Propenoic acid, 3-[4-(1,2-diphenyl-1-butenyl)phenyl]-, (E,Z)-
OTHER NAMES:
CN GW 5638
FS STEREOSEARCH
MF C25 H22 O2
CI COM
SR CA
LC STN Files: BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, DRUGNL, DRUGUPDATES, EMBASE, MEDLINE, PHAR, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

16 REFERENCES IN FILE CA (1967 TO DATE)
16 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:235901

REFERENCE 2: 135:142233

REFERENCE 3: 135:132470

REFERENCE 4: 135:102118

REFERENCE 5: 135:28547

REFERENCE 6: 135:28546

REFERENCE 7: 134:305328

REFERENCE 8: 134:95501

REFERENCE 9: 132:40534

REFERENCE 10: 131:282013

L16 ANSWER 4 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **116057-75-1** REGISTRY
CN Pyrrolidine, 1-[2-[4-[(1E)-1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyrrolidine, 1-[2-[4-[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]-, (E)-
OTHER NAMES:
CN CB 7432
CN Idoxifene
CN SB 223030
FS STEREOSEARCH
MF C28 H30 I N O
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

99 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
100 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:205530

REFERENCE 2: 135:205490

REFERENCE 3: 135:142233

REFERENCE 4: 135:132470

REFERENCE 5: 135:116436

REFERENCE 6: 135:86677

REFERENCE 7: 135:82051

REFERENCE 8: 135:71210

REFERENCE 9: 135:71043

REFERENCE 10: 135:55767

L16 ANSWER 5 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **103199-13-9** REGISTRY
CN Phenol, 3-[(1E)-1-[4-[2-[methyl(phenylmethyl)amino]ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 3-[1-[4-[2-[methyl(phenylmethyl)amino]ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-

FS STEREOSEARCH
MF C32 H33 N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:117261

REFERENCE 2: 132:102844

REFERENCE 3: 129:23441

REFERENCE 4: 123:330040

REFERENCE 5: 105:42468

L16 ANSWER 6 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **97752-20-0** REGISTRY
CN Phenol, 3-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt)
OTHER NAMES:
CN Droloxifene citrate
FS STEREOSEARCH
MF C26 H29 N O2 . C6 H8 O7
SR Commission of European Communities
LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, CHEMLIST, DRUGPAT, DRUGUPDATES, MRCK*, PROMT, RTECS*, SYNTHLINE, TOXLIT, ULIDAT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 82413-20-5

CMF C26 H29 N O2

Double bond geometry as shown.



CM 2

CRN 77-92-9
CMF C6 H8 O7



27 REFERENCES IN FILE CA (1967 TO DATE)
27 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:189063

REFERENCE 2: 132:102844

REFERENCE 3: 131:106847

REFERENCE 4: 130:173031

REFERENCE 5: 130:47499

REFERENCE 6: 129:298396

REFERENCE 7: 129:166227

REFERENCE 8: 129:23441

REFERENCE 9: 128:303587

REFERENCE 10: 128:248582

L16 ANSWER 7 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **89778-26-7** REGISTRY
CN Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

[redacted]

CN Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-
OTHER NAMES:
CN Farestone
CN Toremifene
CN Z-Toremifene
FS STEREOSEARCH
DR 98644-21-4
MF C26 H28 Cl N O
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMLIST, CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, TOXLIT, ULIDAT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

285 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
285 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:302906

REFERENCE 2: 135:288636

REFERENCE 3: 135:266632

REFERENCE 4: 135:251917

REFERENCE 5: 135:251605

REFERENCE 6: 135:220885

REFERENCE 7: 135:205530

REFERENCE 8: 135:205099

REFERENCE 9: 135:204672

REFERENCE 10: 135:190841

L16 ANSWER 8 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **83647-34-1** REGISTRY
CN Phenol, 3-[(1E)-1-[4-[2-(ethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:
CN Phenol, 3-[1-[4-[2-(ethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-
FS STEREOSEARCH
MF C26 H29 N O2
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:117261

REFERENCE 2: 132:102844

REFERENCE 3: 129:23441

REFERENCE 4: 105:42468

REFERENCE 5: 97:215730

L16 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **83647-33-0** REGISTRY
CN Phenol, 3-[(1E)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 3-[1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-
OTHER NAMES:
CN K 106
CN N-Desmethyldroloxifene
FS STEREOSEARCH
MF C25 H27 N O2
LC STN Files: CA, CANCERLIT, CAPLUS, MEDLINE, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
12 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:117261

REFERENCE 2: 132:155208

REFERENCE 3: 132:102844

REFERENCE 4: 129:23441

REFERENCE 5: 128:303587

REFERENCE 6: 123:74089

REFERENCE 7: 121:271199

REFERENCE 8: 121:149116

REFERENCE 9: 119:151738

REFERENCE 10: 105:42468

L16 ANSWER 10 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **83647-31-8** REGISTRY
CN Phenol, 3-[(1E)-1-[4-[2-(diethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 3-[1-[4-[2-(diethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-
OTHER NAMES:
CN K 089
FS STEREOSEARCH
MF C28 H33 N O2
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Double bond geometry as shown.

[redacted]



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:117261

REFERENCE 2: 132:102844

REFERENCE 3: 129:23441

REFERENCE 4: 123:330040

REFERENCE 5: 105:42468

REFERENCE 6: 102:89748

REFERENCE 7: 97:215730

L16 ANSWER 11 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **82413-20-5** REGISTRY
CN Phenol, 3-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-
OTHER NAMES:
CN 3-Hydroxytamoxifen
CN Droloxifene
CN E-Droloxifene
CN K 060
CN K 060E
CN K 21.060E
FS STEREOSEARCH
MF C26 H29 N O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST,

CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXLIT, ULIDAT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

171 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
171 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:267223

REFERENCE 2: 135:205530

REFERENCE 3: 135:132470

REFERENCE 4: 135:117261

REFERENCE 5: 135:76700

REFERENCE 6: 135:71241

REFERENCE 7: 135:14359

REFERENCE 8: 134:348291

REFERENCE 9: 134:305328

REFERENCE 10: 134:305076

L16 ANSWER 12 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **68047-06-3** REGISTRY
CN Phenol, 4-[(1Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-,
(Z)-
OTHER NAMES:
CN (Z)-4-Hydroxytamoxifen
CN 4-Hydroxytamoxifen

CN Hydroxytamoxifen
CN ICI 79280
CN trans-4-Hydroxytamoxifen
CN trans-Hydroxytamoxifen
FS STEREOSEARCH
DR 65213-48-1, 72732-26-4, 76276-99-8
MF C26 H29 N O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IPA, NIOSHTIC, PHAR, PROMT, RTECS*, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

787 REFERENCES IN FILE CA (1967 TO DATE)
24 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
790 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:313320

REFERENCE 2: 135:285335

REFERENCE 3: 135:268424

REFERENCE 4: 135:267692

REFERENCE 5: 135:267192

REFERENCE 6: 135:252144

REFERENCE 7: 135:252083

REFERENCE 8: 135:237592

REFERENCE 9: 135:236600

REFERENCE 10: 135:235901

L16 ANSWER 13 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **64125-60-6** REGISTRY
CN Phenol, 3-methoxy-4-(3-methyl-2-butenyl)-5-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 3-methoxy-4-(3-methyl-2-butenyl)-5-(2-phenylethenyl)-, (E)-
OTHER NAMES:
CN Longistylin C
CN Longistyline C
FS STEREOSEARCH
MF C20 H22 O2
LC STN Files: BEILSTEIN*, CA, CAPLUS, RTECS*, TOXLIT
(*File contains numerically searchable property data)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:105025

REFERENCE 2: 104:126490

REFERENCE 3: 93:37284

REFERENCE 4: 92:110611

REFERENCE 5: 90:183143

REFERENCE 6: 87:117649

L16 ANSWER 14 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **51023-76-8** REGISTRY
CN Benzenesulfonic acid, 5-(acetylamino)-2-[2-(4-isothiocyanato-2-sulfophenyl)ethenyl]-, disodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Disodium 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonate
CN SITS
MF C17 H14 N2 O7 S3 . 2 Na
LC STN Files: ADISINSIGHT, AGRICOLA, BIOBUSINESS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, MSDS-OHS, TOXLIT, USPATFULL
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (27816-59-7)



●2 Na

146 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
146 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:314438

REFERENCE 2: 135:298460

REFERENCE 3: 135:31877

REFERENCE 4: 134:110420

REFERENCE 5: 133:218637

REFERENCE 6: 133:114784

REFERENCE 7: 133:13989

REFERENCE 8: 133:12415

REFERENCE 9: 132:305946

REFERENCE 10: 131:297859

L16 ANSWER 15 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **10540-29-1** REGISTRY
CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-
CN Ethylamine, 2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- (8CI)
OTHER NAMES:
CN ICI 47699
CN Mammaton
CN Tamofen
CN Tamoxifen
CN trans-Tamoxifen
CN Z-Tamoxifen
FS STEREOSEARCH
MF C26 H29 N O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, EMBASE, HSDB*, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER, TOXLIT, ULIDAT, USAN,

USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4094 REFERENCES IN FILE CA (1967 TO DATE)
118 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4108 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:316401

REFERENCE 2: 135:313756

REFERENCE 3: 135:313606

REFERENCE 4: 135:313519

REFERENCE 5: 135:313320

REFERENCE 6: 135:313271

REFERENCE 7: 135:313025

REFERENCE 8: 135:302906

REFERENCE 9: 135:300662

REFERENCE 10: 135:298909

L16 ANSWER 16 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **56-53-1** REGISTRY
CN Phenol, 4,4'-[(1E)-1,2-diethyl-1,2-ethenediyl]bis- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4,4'-Stilbenediol, .alpha.,.alpha.'-diethyl-, (E)- (8CI)
CN Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
OTHER NAMES:
CN (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene
CN (E)-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol
CN (E)-Diethylstilbestrol
CN .alpha.,.alpha.'-Diethyl-4,4'-stilbenediol
CN .alpha.,.alpha.'-Diethylstilbenediol
CN 4,4'-Dihydroxy-.alpha.,.beta.-diethylstilbene
CN 4,4'-Dihydroxydiethylstilbene

CN Agostilben
CN Antigestil
CN Bio-des
CN Bufon
CN Comestrol
CN Cyren
CN Cyren A
CN Dawe's destrol
CN DEB
CN DES
CN DES (synthetic estrogen)
CN Di-Estryl
CN DiBestrol 2 Premix
CN Diethylstilbestrol
CN Distilbene
CN Domestrol
CN Estilbin MCO
CN Estrobene
CN Estromenin
CN Estrosyn
CN Fonatol
CN Grafestrol
CN Hi-Bestrol
CN Iscovesco
CN Menostilbeen
CN Microest
CN Milestrol
CN Neo-Oestranol I
CN Oestrogenine
CN Oestromenin
CN Oestromensyl
CN Pabestrol
CN Palestrol
CN Rumestrol 1
CN Rumestrol 2
CN Serral
CN Sexocretin
CN Sibol
CN Stil
CN Stil-Rol
CN Stilbestrol
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS STEREOSEARCH
DR 8026-45-7, 8028-09-9, 8030-34-0, 8049-42-1, 8053-00-7
MF C18 H20 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLIT, ULIDAT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4816 REFERENCES IN FILE CA (1967 TO DATE)
91 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4821 REFERENCES IN FILE CAPLUS (1967 TO DATE)
35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:314622

REFERENCE 2: 135:313797

REFERENCE 3: 135:313320

REFERENCE 4: 135:303215

REFERENCE 5: 135:299875

REFERENCE 6: 135:288636

REFERENCE 7: 135:288504

REFERENCE 8: 135:286909

REFERENCE 9: 135:284382

REFERENCE 10: 135:284251

L16 ANSWER 17 OF 17 REGISTRY COPYRIGHT 2001 ACS
RN **50-41-9** REGISTRY
CN Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]-, citrate (1:1) (8CI)
CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]-, citrate (6CI, 7CI)
OTHER NAMES:
CN 1-[p-(.beta.-Diethylaminoethoxy)phenyl]-1,2-diphenyl-2-chloroethylene citrate
CN 2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine dihydrogen citrate
CN Chloramiphene
CN Clomid
CN Clomifene citrate
CN Clomifeno
CN Clomiphene citrate
CN Clomiphene dihydrogen citrate
CN Clomivid
CN Clomphid

CN Clostilbegyt
CN Dyneric
CN Fertivet
CN Fertyl
CN Genozym
CN Ikaclomin
CN Mer 41
CN MRL 41
CN Omifin
CN Racemic clomiphene citrate
MF C26 H28 Cl N O . C6 H8 O7
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DIOGENES, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, NIOSHTIC, PHARMASEARCH, PROMT, RTECS*, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 911-45-5
CMF C26 H28 Cl N O



CM 2

CRN 77-92-9
CMF C6 H8 O7



644 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
646 REFERENCES IN FILE CAPLUS (1967 TO DATE)
25 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:268418

REFERENCE 2: 135:267389

REFERENCE 3: 135:221503

REFERENCE 4: 135:221432

REFERENCE 5: 135:221411

REFERENCE 6: 135:205651

REFERENCE 7: 135:116199

REFERENCE 8: 135:71383

REFERENCE 9: 134:290552

REFERENCE 10: 134:285588

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 09:57:22 ON 19 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1947 - 19 Nov 2001  VOL 135 ISS 22
FILE LAST UPDATED: 18 Nov 2001  (20011118/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 This file supports REGISTRY for direct browsing and searching of
 all substance data from the REGISTRY file.  Enter HELP FIRST for
 more information.

HCAplus now provides online access to patents and literature covered
in CA from 1947 to the present.  On April 22, 2001, bibliographic
information and abstracts were added for over 2.2 million references
published in CA from 1947 to 1966.

=>

=>

=> d stat que l19
L1                  STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE
L7         65281 SEA FILE=REGISTRY SSS FUL L1
L11        40827 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7
L12           99 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11(L)(BONE(2A)(LOSS OR
                 RESORP?) OR ?OSTEOPO? OR ?HYPERTENS? OR (BLD OR BLOOD)(W)PRESSU
                 RE)
L14          978 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7(L)(?MEDIC? OR ?PHARM? OR
```

```
               ?DRUG? OR ?THERP?)
L15            10 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L14 AND L12
L18            61 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12 NOT (2001 OR 2000 OR
                  1999)/PY
L19            56 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L18 NOT L15


=>
=>

=> d ibib abs hitrn l19 1-25;d ibib hitrn l19 26-56

L19  ANSWER 1 OF 56  HCAPLUS  COPYRIGHT 2001 ACS
ACCESSION NUMBER:         1998:763283  HCAPLUS
DOCUMENT NUMBER:          130:119562
TITLE:                    Idoxifene: a novel selective estrogen receptor
                          modulator prevents bone loss and lowers cholesterol
                          levels in ovariectomized rats and decreases uterine
                          weight in intact rats
AUTHOR(S):                Nuttall, Mark E.; Bradbeer, Jeremy N.; Stroup, George
                          B.; Nadeau, Daniel P.; Hoffman, Sandra J.; Zhao, Hugh;
                          Rehm, Sabine; Gowen, Maxine
CORPORATE SOURCE:         Departments of Bone and Cartilage Biology, and Safety
                          Assessment (SR), SmithKline Beecham Pharmaceuticals,
                          King of Prussia, PA, 19406, USA
SOURCE:                   Endocrinology (1998), 139(12), 5224-5234
                          CODEN: ENDOAO; ISSN: 0013-7227
PUBLISHER:                Endocrine Society
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   Idoxifene, a novel selective estrogen receptor modulator, was tested for
     its effects on bone loss, serum cholesterol, and uterine wet wt. and
     histol. in the ovariectomized (Ovx) rat. Idoxifene (0.5 mg/kg.cntdot.day)
     completely prevented loss of both lumbar and proximal tibial bone mineral
     d. (BMD). In an intervention study, idoxifene (0.5 and 2.5
     mg/kg.cntdot.day) completely prevented further loss of both lumbar and
     proximal tibial BMD during a 2-mo treatment period commencing 1 mo after
     surgery, when significant loss of BMD had occurred in the Ovx control
     group. Idoxifene reduced total serum cholesterol, which was maximal at
     0.5 mg/kg.cntdot.day. Idoxifene alone displayed minimal uterotrophic
     activity in Ovx rats and inhibited the agonist activity of estrogen in
     intact rats. Histol., myometrial and endometrial atrophy were obsd. in
     both idoxifene and vehicle-treated Ovx rats. The authors also provide
     mol.-based evidence to support the observations in vivo of a novel
     selective estrogen receptor modulator (SERM) mechanism of action in bone
     and endometrial cells. Idoxifene is an agonist through the estrogen
     response element (ERE) and exhibits similar postreceptor effects to
     estrogen in bone-forming osteoblasts. Idoxifene also stimulates
     osteoclast apoptosis, and these pleiotropic effects ultimately could
     contribute to the maintenance of bone homeostasis. However, idoxifene
     differs from estrogen in a tissue-specific manner. In human endometrial
     cells, where estrogen is a potent agonist through the ERE, idoxifene has
     negligible agonist activity. Moreover, idoxifene was able to block
     estrogen induced gene expression in endometrial cells, which is in
     agreement with the observation in the intact rat study. In the uterus,
     idoxifene has a pharmacol. favorable profile, lacking agonist and
     therefore growth-promoting activity. Together with its cholesterol
     lowering effect and lack of uterotrophic activity, these data suggest that
     idoxifene may be effective in the prevention of osteoporosis and other
```

postmenopausal diseases without producing unwanted estrogenic effects on the endometrium.

IT **116057-75-1**, Idoxifene
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(idoxifene prevents **bone loss** and lowers cholesterol levels in ovariectomized rats and decreases uterine wt. in intact rats)

REFERENCE COUNT: 46
REFERENCE(S):
(3) Beresford, J; Endocrinology 1986, V119, P1776 HCAPLUS
(6) Chander, S; Cancer Res 1991, V51, P5851 HCAPLUS
(7) Clover, J; Bone 1994, V15, P585 HCAPLUS
(9) Frenkel, B; Biochemistry 1993, V32, P13636 HCAPLUS
(10) Furr, B; The Pharmacology and clinical uses of tamoxifen Pharmacol Therap 1984, V25, P127 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1998:430074 HCAPLUS
DOCUMENT NUMBER: 129:100036
TITLE: Combination therapy to treat osteoporosis - polyphosphonates and estrogen agonists
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5773477	A	19980630	US 1997-803707	19970221

OTHER SOURCE(S): MARPAT 129:100036
GI



I

AB A novel method of treating or preventing osteoporosis in mammals comprises administering an effective amt. of an estrogen agonist (I; R1, R2 =, Me, Et, PhCH2; when R1 = R2, each is Me or Et; when R1 .noteq. R2, one is Me or Et and the other is H or PhCH2) or pharmaceutically acceptable salt thereof, together with a bone resorption-inhibiting polyphosphonate. Thus, tablets were prepd. contg. active ingredients 0.25-100, starch 45, microcryst. cellulose 35, PVP (as 10% aq. soln.) 4, Na CM-cellulose 4.5, Mg stearate 0.5, and talc 1 wt. parts.

IT **165813-04-7**
RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(5combination therapy to treat **osteoporosis**: polyphosphonates and estrogen agonists)

IT **165813-01-4 165813-02-5 165813-03-6**
209684-21-9 209684-24-2 209684-27-5
209684-29-7 209684-31-1 209684-33-3
209684-35-5 209684-38-8
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy to treat **osteoporosis**: polyphosphonates and estrogen agonists)

L19 ANSWER 3 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1998:402319 HCAPLUS
DOCUMENT NUMBER: 129:86015
TITLE: Methods and compositions for preventing and treating bone loss
INVENTOR(S): Fuh, Vivian L.; Kaufman, Keith D.; Waldstreicher, Joanne
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Fuh, Vivian L.; Kaufman, Keith D.; Waldstreicher, Joanne
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825623	A1	19980618	WO 1997-US22344	19971205
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9855943	A1	19980703	AU 1998-55943	19971205

PRIORITY APPLN. INFO.:
US 1996-32635 19961209
GB 1997-221 19970108
US 1997-47174 19970520
WO 1997-US22344 19971205

AB The present invention provides for a method of inhibiting bone loss in a subject in need of such treatment comprising administration of a therapeutically effective amt. of the 5.alpha.-reductase type 2 inhibitor finasteride to the subject. The present invention further provides for a method for treating and preventing osteoporosis and osteopenia and other diseases where inhibiting bone loss may be beneficial, including: Paget's disease, malignant hypercalcemia, periodontal disease, joint loosening and metastatic bone disease, comprising administration of therapeutically effective amt. of the 5.alpha.-reductase type 2 inhibitor finasteride to the subject. Further, the present invention provides for compns. useful in the methods of the present invention, as well as a method of manuf. of a medicament useful for inhibiting bone loss and treating or preventing osteoporosis and osteopenia. The effect of finasteride on bone mineral d. in men was studied and formulations contg. finasteride were given. Bone anabolic agents, bone antiresorptive agents, estrogens, or antiestrogens may be added to the compns.

IT **911-45-5**, Clomiphene **5863-35-4**, CI-628
15690-55-8, Zuclomiphene **15690-57-0**, Enclomiphene
56287-31-1, CI-680
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5.alpha.-reductase type 2 inhibitor compns. for preventing and treating **bone loss**)

L19 ANSWER 4 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1998:402318 HCAPLUS
DOCUMENT NUMBER: 129:67926
TITLE: Methods and compositions for preventing and treating bone loss
INVENTOR(S): Fuh, Vivian L.; Kaufman, Keith D.; Waldstreicher, Joanne
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Fuh, Vivian L.; Kaufman, Keith D.; Waldstreicher, Joanne
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825622	A1	19980618	WO 1997-US22050	19971205
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9857916	A1	19980703	AU 1998-57916	19971205

PRIORITY APPLN. INFO.: US 1996-32636 19961209
GB 1997-220 19970108
WO 1997-US22050 19971205

OTHER SOURCE(S): MARPAT 129:67926
GI



I



II

AB Azasteroids of formula I [R1 = H, alkyl; R2, R3 = alkyl] are prepd. for use in inhibiting bone loss. The present invention further provides for a

method for treating and preventing osteoporosis and osteopenia and other diseases where inhibiting bone loss may be beneficial, including: Paget's disease, malignant hypercalcemia, periodontal disease, joint loosening and metastatic bone disease, comprising administration of therapeutically effective amt. of I to the subject. Thus, II is prepd. from pregnenolone acetate in several steps. Pharmaceutical compns. contg. I are described.

IT **911-45-5**, Clomiphene **5863-35-4**, CI-628
15690-55-8, Zuclomiphene **15690-57-0**, Enclomiphene
56287-31-1, CI-680
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of azasteroids for preventing and treating **bone loss**)

L19 ANSWER 5 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:273968 HCAPLUS
DOCUMENT NUMBER: 126:338657
TITLE: Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats
AUTHOR(S): Jimenez, M. A.; Magee, D. E.; Bryant, H. U.; Turner, R. T.
CORPORATE SOURCE: Department Orthopedics Biochemistry Molecular Biology, Mayo Clinic, Rochester, MN, 55905, USA
SOURCE: Endocrinology (1997), 138(5), 1794-1800
CODEN: ENDOAO; ISSN: 0013-7227
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Estrogen inhibits postmenopausal bone loss and decreases fracture risk. Unfortunately, estrogen replacement therapy has many undesirable side effects, the majority of which are due to stimulation of reproductive tissues. Tissue specific estrogen agonists provide a promising new alternative to natural estrogens for hormone replacement. Clomiphene (CLO) is a substituted triphenylethylene antiestrogen based on its ability to antagonize estrogen-mediated uterine growth in rodents. CLO is used clin. for the treatment of disorders of ovulation in patients wishing to become pregnant. To det. whether CLO has tissue selective actions, we performed a dose-response study in adult (6-mo-old) ovariectomized (OVX'd) rats. the rats received daily (gavage) doses of either 17 .alpha.-ethynylestradiol (E) (0.1 mg/kg) or CLO (0.01-10 mg/kg) daily for 5 wk. Long-term loss of ovarian function had no effect on serum cholesterol, greatly decreased uterine wt., cancellous bone area and trabecular no., and increased bone formation rate (BFR) and osteoblast and osteoclast perimeters. E treatment of OVD'd rats prevented uterine atrophy, greatly lowered cholesterol, and prevented many of the bone changes. CLO was a very weak estrogen agonist in supporting uterine wt., a partial agonist in reducing serum cholesterol, and an excellent agonist in maintaining normal bone mass and indexes of bone turnover. We conclude from these studies that CLO exhibits pronounced tissue selective estrogen agonism in the rat. Specifically, CLO is effective in preventing cancellous bone loss in the OVD'd rats and has minimal uterotrophic activity.

IT **911-45-5**, Clomiphene
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(clomiphene prevents cancellous **bone loss** from tibia of ovariectomized rats)

L19 ANSWER 6 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:214315 HCAPLUS
DOCUMENT NUMBER: 126:272315
TITLE: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study
AUTHOR(S): Delmas, P.D.; Balena, R.; Confravreux, E.; Hardouin, C.; Hardy, P.; Bremond, A.
CORPORATE SOURCE: INSERM Research Unit 403, Hopital E. Herriot, Lyon, 69437, Fr.
SOURCE: J. Clin. Oncol. (1997), 15(3), 955-962
CODEN: JCONDN; ISSN: 0732-183X
PUBLISHER: Saunders
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The purpose of this study is to det. the effectiveness and safety of the bisphosphonate risedronate in preventing bone loss in young women with breast cancer and early menopause induced by chemotherapy who are at major risk for the development of postmenopausal osteoporosis. Fifty-three white women, aged 36 to 55 yr, with breast cancer and artificially induced menopause were stratified according to prior tamoxifen use. Thirty-six patients received tamoxifen (20 mg/d). Within each stratum, patients were randomly assigned to receive risedronate (n = 27) or placebo (n = 26). Treatment consisted of eight cycles oral risedronate 30 mg/d or placebo daily for 2 wk followed by 10 wk of no drug (12 wk per cycle). Patients were monitored for a third year without treatment. Main outcomes of the study were changes in lumbar spine and proximal femur (femoral neck, trochanter, and Ward's triangle) bone mineral d. (BMD), and biochem. markers of bone turnover. In contrast to a significant decrease of BMD at the lumbar spine and hip in the placebo group, there was an increase in BMD in the risedronate group. On treatment withdrawal, bone loss ensued, which suggests that treatment needs to be continuous to maintain a protective effect on bone mass. At 2 yr, the mean difference (.+-. SEM) between groups was 2.5% .+-. 1.2%, (95% confidence interval [CI], 0.2 to 4.9) at the lumbar spine (P = .041) and 2.6% .+-. 1.1%, (95% CI, 0.3 to 4.8) at the femoral neck (P = .029). Similar results were obsd. at the hip trochanter. Results by stratum indicate a beneficial, although partial, effect of tamoxifen in reducing bone loss. Risedronate was well tolerated and showed a good safety profile, with no evidence of lab. abnormalities. Risedronate appears to be a safe treatment that prevents both trabecular and cortical bone loss in women with menopause induced by chemotherapy for breast cancer.

IT **10540-29-1**, Tamoxifen
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bisphosphonate risedronate prevents **bone loss** in women with artificial menopause due to chemotherapy of breast cancer)

L19 ANSWER 7 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1996:312445 HCAPLUS
DOCUMENT NUMBER: 125:25752
TITLE: Regulation of avian osteoclastic H+-ATPase and bone resorption by tamoxifen and calmodulin antagonists. Effects independent of steroid receptors
AUTHOR(S): Williams, John P.; Blair, Harry C.; McKenna, Margaret A.; Jordan, S. Elizabeth; McDonald, Jay M.
CORPORATE SOURCE: Dep. Pathol., Univ. Alabama, Birmingham, AL, 35294, USA

SOURCE: J. Biol. Chem. (1996), 271(21), 12488-12495
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We used highly purified chicken osteoclasts and isolated membranes from osteoclasts to study effects of tamoxifen, 4-hydroxytamoxifen, calmodulin antagonists, estrogen, diethylstilbestrol, and the anti-estrogen ICI 182780 on cellular degrdn. of 3H-labeled bone in vitro and on membrane HCl transport. Bone resorption was reversibly inhibited by tamoxifen, 4-hydroxytamoxifen, and trifluoperazine with IC50 values of .apprx.1 .mu.M. Diethylstilbestrol and 17-.beta.-estradiol had no effects on bone resorption at receptor-satg. concns., while ICI 182780 inhibited bone resorption at concns. greater than 1 .mu.M. At these concns. ICI 182780, like tamoxifen, inhibits calmodulin-stimulated cyclic nucleotide phosphodiesterase activity. Membrane HCl transport, assessed by ATP-dependent acridine orange uptake, was unaffected by 17-.beta.-estradiol and diethylstilbestrol at concns. up to 10 .mu.M, whole ICI 182780 inhibited HCl transport at concns. greater than 1 .mu.M. In contrast HCl transport was inhibited by tamoxifen, 4-hydroxytamoxifen, and the calmodulin antagonists, trifluoperazine and calmidazolium, with IC50 values of 0.25-1.5 .mu.M. These results suggested the presence of a membrane-assocd. non-steroid receptor for tamoxifen in osteoclasts. Tamoxifen binding studies demonstrated saturable binding in the osteoclast particulate fraction, but not in the nuclear or cytosolic fractions. Membranes enriched in ruffled border by differential centrifugation following nitrogen cavitation showed binding consistent with one site, Kd .apprx.1 .mu.M. Our findings indicate that tamoxifen inhibits osteoclastic HCl transport by binding membrane-assocd. target(s), probably similar or related to calmodulin antagonist targets. Further, effects of estrogens or highly specific anti-estrogens on bone turnover do not support the hypothesis of a direct effect on osteoclasts by these compds. in this species.

IT **10540-29-1**, Tamoxifen
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(regulation of avian osteoclastic H+-ATPase and **bone resorption** by tamoxifen and calmodulin antagonists is independent of steroid receptors)

L19 ANSWER 8 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1996:82434 HCAPLUS
DOCUMENT NUMBER: 124:134461
TITLE: Organ-selective actions of tamoxifen and other partial antiestrogens
AUTHOR(S): Turner, R. T.
CORPORATE SOURCE: Dep. Orthop. Res., Mayo Clin. Found., Rochester, NY, 55905, USA
SOURCE: Ernst Schering Res. Found. Workshop (1995), Volume Date 1995, 16, 65-84
CODEN: ESRWEL; ISSN: 0947-6075
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with many refs. of prevention of and therapy for postmenopausal osteoporosis with estrogen agonists and antagonists.

IT **10540-29-1**, Tamoxifen
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(organ-selective actions of tamoxifen and other partial antiestrogens and therapy for postmenopausal **osteoporosis**)

L19 ANSWER 9 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1996:26510 HCAPLUS
DOCUMENT NUMBER: 124:105293
TITLE: Anti-estrogens and postmenopausal osteoporosis
AUTHOR(S): Draper, Michael W.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
SOURCE: J. Bone Miner. Metab. (1994), Volume Date 1994, 12(Suppl. 2), S21-S23
CODEN: JBMME4; ISSN: 0914-8779
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 8 refs. Many agents in the estrogen-antiestrogen class may have potential as effective antiresorptives in the treatment of osteoporosis. Several studies have now established the therapeutic potential of tamoxifen in this field. Raloxifene is a new agent, which may show promise in the therapy of osteoporosis.
IT **10540-29-1**, Tamoxifen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-estrogens and postmenopausal **osteoporosis**)

L19 ANSWER 10 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1996:17239 HCAPLUS
DOCUMENT NUMBER: 124:106966
TITLE: Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats
AUTHOR(S): Ke, H. Z.; Chen, H. K.; Qi, H.; Pirie, C. M.; Simmons, H. A.; Ma, Y. F.; Jee, W. S. S.; Thompson, D. D.
CORPORATE SOURCE: Department Metabolic Diseases, Pfizer Inc., Groton, CT, 06340, USA
SOURCE: Bone (1995), 17(5), 491-6
CODEN: BONEDL; ISSN: 8756-3282
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The purpose of this study was to det. the efficacy of droloxifene (DRO), an estrogen antagonist/agonist, in preventing ovariectomy (OVX)-induced lumbar vertebral cancellous bone loss and bone turnover in aged female rats. Fifty-three Sprague-Dawley female rats were OVX or sham-operated at 19 mo of age, and divided into 6 groups: (I) sham-operated controls; (II) OVX vehicle controls; (III) OVX rats treated with E2 at 30 .mu.g/kg/day; (IV)-(VI) OVX rats treated with DRO at either 2.5, 5, or 10 mg/kg p.o. daily. The treatment period was 8 wk. Static and dynamic cancellous bone histomorphometric parameters were detd. on 4 and 10 .mu.m thick, undecalcified, double-fluorescent labeled sections of the fourth lumbar vertebral body. Changes in body wt., uterine wt., and total serum cholesterol were also detd. OVX for 8 wk in 19-mo-old female rats resulted in reduced trabecular bone vol. (-18%) and trabecular width (-10%) and increased labeling perimeter (+52%), bone formation rate/bone surface referent (+60%), bone formation rate/bone vol. referent (+77%), osteoclast no. (+41%), and osteoclast perimeter (+41%). E2 treatment at 30 .mu.g/kg/day for 8 wk prevented OVX-induced cancellous bone loss and decreased bone resorption, bone formation, and bone turnover to the values of sham controls. DRO at 2.5-10 mg/kg/day completely prevented bone loss and bone turnover assocd. with estrogen deficiency. Osteoclast no. and perimeter were significantly decreased in DRO-treated-OVX rats compared to both sham and OVX controls. Trabecular bone vol., trabecular width, labeling perimeter, bone formation rate/bone surface referent, and bone

formation rate/bone vol. referent showed no differences in DRO-treated OVX rats compared to those of E2-treated OVX rats and sham controls. These histomorphometric results indicated that DRO is an estrogen agonist on cancellous bone of lumbar vertebral bodies of aged, OVX rats. Further, E2 treatment prevented the OVX-induced increase in body wt. gain and nonsignificantly reduced total serum cholesterol compared to OVX controls. Body wt. gain and total serum cholesterol did not differ between OVX rats treated with E2 and sham controls. In OVX rats treated with DRO, body wt. decreased significantly in a dose-response manner, and total serum cholesterol was significantly reduced by 65% to 70% compared to both sham and OVX controls. In addn., treatment with E2 increased uterine wt. to the value of sham controls in OVX rats. However, DRO had no effect on uterine wt. at either 2.5 or 10 mg/kg/day, while it only slightly but significantly increased uterine wt. over OVX controls at 5 mg/kg/day. The authors conclude that DRO was efficacious in the prevention of lumbar vertebral cancellous bone loss and in the decline of total serum cholesterol but had no effect on uterine wt. in the aged, OVX female rats. The data suggest that DRO is a potentially useful agent for the prevention of vertebral bone loss leading to spinal fractures in postmenopausal women.

IT **82413-20-5**, Droloxifene
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of droloxifene on prevention of cancellous **bone loss** and **bone** turnover in axial skeleton of aged, ovariectomized rats)

L19 ANSWER 11 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:730370 HCAPLUS
DOCUMENT NUMBER: 123:160785
TITLE: Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy x-ray absorptiometric and histomorphometric study
AUTHOR(S): Chen, Hong Ka; Ke, Hua Zhu; Jee, Webster S. S.; Ma, Yan Fei; Pirie, Christine M.; Simmons, Hollis A.; Thompson, David D.
CORPORATE SOURCE: Division of Radiobiology, Univ. of Utah Sch. of Medicine, Salt Lake City, UT, USA
SOURCE: J. Bone Miner. Res. (1995), 10(8), 1256-62
CODEN: JBMREJ; ISSN: 0884-0431
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Our previous studies indicated that droloxifene (DRO), a tissue-specific estrogen antagonist/agonist, prevented bone loss without causing uterine hypertrophy is growing ovariectomized (OVX) rats. Using dual-energy x-ray absorptiometry (DXA) and bone histomorphometry, the current study compared the efficacy of DRO to 17.beta.-estradiol (E2) in preventing OVX-induced bone loss in tibiae and femora of 19-mo-old rats to det. whether DRO had similar skeletal effects as E2 in aged female rats. Sprague-Dawley female rats were OVX or sham-operated (sham) at 19 mo of age. The sham-operated rats were treated with vehicle (oral), while the OVX rats were treated with vehicle (oral), E2 at 30 .mu.g/kg/day (s.c.), or DRO at 2.5, 5, or 10 mg/kg/day (oral) for 8 wk. Bone mineral d. (BMD) of whole femora (WF), distal femoral metaphyses (DFM), femoral shafts (FS), and proximal femora (PF) was detd. using DXA. Static and dynamic cancelous bone histomorphometric analyses were performed in double-labeled undecalcified longitudinal sections from proximal tibial metaphyses. Ovariectomy for 8 wk significantly reduced the BMD of WF, DFM, FS, and PF (from -6 to -15%). Treatment with E2 completely prevented the decreases in BMD of WF and DFM

and had no significant effects in BMD of FS and PF in aged OVX rats. The decrease in BMD of DFM induced by OVX was prevented by treatment with DRO at all dose levels. In addn., DRO at 10 mg/kg/day prevented OVX-induced decreases in BMD of WF, FS, and PF. Furthermore, proximal tibial cancellous bone histomorphometric results showed that OVX significantly decreased the trabecular bone vol. by 34% and increased the activation frequency by 104% while it nonsignificantly increased other indexes including percent eroded perimeter, mineral apposition rate, and bone formation rate per bone vol. compared with sham-operated controls. Treatment with E2 or DRO at all dose levels completely prevented the OVX-induced decreases in trabecular bone vol. and increases in bone turnover, indicating that DRO is an estrogen agonist in bone in aged OVX rats. Together with the previous findings that DRO inhibited body wt. gain, reduced total serum cholesterol, and had no effect on uterine wt., we conclude that DRO is as efficacious as E2 in preventing OVX-induced bone loss and inhibiting bone turnover but without estrogenic uterine effects in aged OVX rats. These data suggest that DRO may be superior to E2 for the treatment of postmenopausal and senile osteoporosis.

IT **82413-20-5**, Droloxifene
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(droloxifene prevention of ovariectomy-induced **bone loss** in relation to **osteoporosis** treatment)

L19 ANSWER 12 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:575349 HCAPLUS
DOCUMENT NUMBER: 122:306275
TITLE: Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats
AUTHOR(S): Ke, Hua Zhu; Simmons, Hollis A.; Pirie, Christine M.; Crawford, D. Todd; Thompson, David D.
CORPORATE SOURCE: Dep. Cardiovascular Metabolic Siseases, Central Res. Div., Groton, CT, 06340, USA
SOURCE: Endocrinology (1995), 136(6), 2435-41
CODEN: ENDOAO; ISSN: 0013-7227
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The purpose of this study was to det. the effects of droloxifene (DRO), a new estrogen antagonist/agonist, on bone turnover, bone mass, total serum cholesterol, and uterine wt. in rats made estrogen deficient by ovariectomy. Sprague-Dawley female rats were ovariectomized (OVX) or sham operated (sham) at 5 mo of age and treated with 17.beta.-estradiol (E2) at 30 .mu.g/kg, s.c., daily or with DRO at 5, 10, or 20 mg/kg.cntdot.day, orally, for 4 wk. At the time of death, body wt. gain, uterine wt., and total serum cholesterol were measured. Bone area, bone mineral content (BMC), and bone mineral d. (BMD) of whole femora, distal femoral metaphases, femoral shaft, and proximal femora were detd. ex vivo using dual energy x-ray absorptiometry. Static and dynamic cancellous bone histomorphometric anal. of proximal tibial metaphyses was performed in double fluorescent labeled, undecalcified, 4- and 10-.mu.m longitudinal sections. Body wt. gain in E2-treated OVX rats was significantly reduced compared to that in OVX controls, but was not different from that in sham controls. Body wt. gain in DRO-treated OVX rats was decreased significantly compared to that in both sham and OVX controls. In OVX rats, uterine wt. was completely preserved by treatment with E2. Uterine wt. in DRO-treated OVX rats was slightly, but significantly, increased from the vehicle-treated control value, and was significantly lower than that in sham controls and E2-treated OVX rats. Treatment with s.c. injection of E2 in OVX rats had no effect on total serum cholesterol,

whereas OVX rats orally treated with DRO at 5-20 mg/kg.cntdot.day decreased total serum cholesterol by 33-46% compared to levels in sham and OVX controls. Compared to sham controls, OVX decreased BMC and BMD of distal femoral metaphyses, increased BMD of the femoral shaft, and had no effect on BMC and BMD of whole femora and proximal femora. Treatment with either E2 or DRO prevented these changes induced by OVX. Proximal tibial metaphyseal trabecular bone vol. and trabecular no. were increased, and trabecular sepn., percent osteoclast perimeter, osteoclast no., percent mineralizing perimeter, mineral apposition rate, bone formation rate, and bone turnover rate were decreased in 5, 10, or 20 mg/kg.cntdot.day DRO-treated OVX rats compared to OVX controls. These cancellous bone histomorphometric indexes in DRO-treated OVX rats did not differ from those in E2-treated OVX rats or sham controls, suggesting that DRO completely prevented the increases in bone turnover and the decrease in bone mass induced by OVX in rats. The results demonstrate that DRO prevented increased bone turnover and bone loss, reduced total serum cholesterol, and caused minimal uterine hypertrophy in 5-mo-old OVX rats. These data suggest that DRO is an estrogen agonist on bone and may be an effective alternative to estrogen for the prevention of postmenopausal osteoporosis.

IT **82413-20-5**, Droloxifene
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(droloxifene, a new estrogen antagonist/agonist, prevents **bone loss** in ovariectomized rats)

L19 ANSWER 13 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:417462 HCAPLUS
DOCUMENT NUMBER: 122:170182
TITLE: Therapeutics for treatment of osteoporosis
INVENTOR(S): Miki, Shuji; Kanehira, Koichi; Matsumoto, Toshio
PATENT ASSIGNEE(S): Kuraray Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06312930	A2	19941108	JP 1993-128036	19930430

AB The title therapeutic compns. (e.g. tablets) contain progestogens and estrogen antagonists as active ingredients. Administration of progesterone (I) and 16.beta.-ethylestradilol (II) at 25 mg/kg and 50 .mu.g/kg, resp., s.c. for 2 wk to bone morphogenetic protein-treated rats resulted in bone mineral increase by 60%, vs. -6% or 14%, resp. for I or II alone.

IT **10540-29-1**, Tamoxifen
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mixt. contg., combination use of progestogens and estrogen antagonists for treatment of **osteoporosis**)

L19 ANSWER 14 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:333200 HCAPLUS
DOCUMENT NUMBER: 122:96017
TITLE: Antiestrogens inhibit in vitro bone resorption stimulated by 1,25-dihydroxyvitamin D3 and the vitamin

D3 analogs EB1089 and KH1060
AUTHOR(S): Vink-van Wijngaarden, Trudy; Birkenhaeger, Jan C.; Kleinekoort, Wendy M. C.; van den Bernd, Gert-Jan C. M.; Pols, Huibert A. P.; van Leeuwen, P. T. M.
CORPORATE SOURCE: Dep. Internal Med. III, Erasmus Univ. Med. Sch., Rotterdam, 3000 DR, Neth.
SOURCE: Endocrinology (1995), 136(2), 812-15
CODEN: ENDOAO; ISSN: 0013-7227
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3) has been shown to inhibit breast cancer cell growth both in vitro and in vivo. A major drawback is that high doses of 1,25-(OH)2D3 are needed which may result in undesirable side effects like the development of hypercalcemia and an increased risk of bone metastases due to the stimulation of bone resorption by 1,25-(OH)2D3. Several newly developed 1,25-(OH)2D3 analogs have a reduced calcemic activity, but their effects on bone resorption have not yet been examd. Presently, the antiestrogen tamoxifen is the most important endocrine therapy for breast cancer. Recent studies have demonstrated the benefit of the combination tamoxifen and 1,25-(OH)2D3/analogs for the inhibition of breast cancer cell growth. Besides inhibition of breast cancer growth tamoxifen appeared to have beneficial effects on bone. The purpose of the present study was to investigate the effect of tamoxifen on 1,25-(OH)2D3- and analogs (EB 1089 and KH 1060)-stimulated bone resorption in an in vitro model. Bone resorption was stimulated by 1,25-(OH)2D3 and analogs in a dose-dependent manner with KH 1060 and EB 1089 being more potent than 1,25-(OH)2D3. Tamoxifen caused a strong dose-dependent inhibition (70% at 10 .mu.M) of 1,25-(OH)2D3- and EB 1089-stimulated bone resorption. KH 1060-stimulated bone resorption was also inhibited by tamoxifen but to a lesser extent (36%). Also the pure antiestrogen ICI164,384 but not 17.beta.-estradiol inhibited 1,25-(OH)2D3-stimulated bone resorption. Together, this study demonstrates that tamoxifen considerably reduces 1,25-(OH)2D3/analogs-stimulated bone resorption and therefore may be useful to reduce the risk of bone metastases. This together with the obsd. beneficial effects on breast cancer cell growth indicates that tamoxifen together with 1,25-(OH)2D3/analogs is an interesting combination for the treatment of breast cancer. The mechanism of the bone resorption inhibitory action is not yet known but seems to be independent of the estrogen pathway.

IT **10540-29-1**, Tamoxifen
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiestrogens inhibit in vitro **bone resorption** stimulated by 1,25-dihydroxyvitamin D3 and vitamin D3 analogs EB1089 and KH1060)

L19 ANSWER 15 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1994:646209 HCAPLUS
DOCUMENT NUMBER: 121:246209
TITLE: In the ovariectomized rat, tamoxifen conserves bone similarly in parathyroid-intact and parathyroidectomized animals
AUTHOR(S): Goulding, A.; Gold, E.
CORPORATE SOURCE: Department Medicine, University Otago, Dunedin, N. Z.
SOURCE: Bone (1994), 15(5), 497-503
CODEN: BONEDL; ISSN: 8756-3282
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To examine the ability of tamoxifen (TAM) to conserve bone in the

estrogen-deficient ovariectomized (OVX) rat in the presence and absence of parathyroid hormone (PTH) six groups of rats with 45Ca-labeled bones were studied for 12 wk. Rats were OVX, parathyroidectomized (PTX), or given sham operations and treated with TAM (10 mg/kg body wt./wk s.c.) or TAM-vehicle. Treatments were: group 1 = Sham-OVX; group 2 = Sham-OVX + TAM; group 3 = OVX; group 4 = OVX + TAM; group 5 = OVX + PTX; and group 6 = OVX + PTX + TAM. To monitor bone resorption serial measurements of urinary hydroxyproline and 45Ca excretion were made during the study. Ovariectomy raised these markers of bone breakdown and caused significant osteopenia, whereas TAM prevented ovariectomy increasing urinary hydroxyproline or 45Ca and conserved bone. Final total body calcium values (TBCa) in groups 1-6, resp., were (mg .+-. SD): 3240 .+-. 300; 3260 .+-. 289; 2750 .+-. 231; 3212 .+-. 312; 2742 .+-. 199; and 3387 .+-. 252. Thus ovariectomy reduced TBCa similarly in the presence and absence of the parathyroids ($p < 0.001$). In contrast TAM fully protected both PT-intact and PTX rats from the osteopenic effect of ovariectomy, despite the fact that PTX rats had a lower rate of bone turnover than PT-intact rats. However, TAM-treated OVX rats had shorter femora than OVX rats given TAM-vehicle, suggesting that TAM suppresses growth of the long bones to some degree in estrogen-deficient animals. We conclude that, in the rat, TAM conserves the skeleton from estrogen-deficiency bone loss independently of changes in PT function. Estrogen-deficiency bone loss is no greater in rats with a high rate of PTH-mediated bone breakdown than in rats with a low rate of PTH-mediated bone turnover.

IT **10540-29-1**, Tamoxifen
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tamoxifen conserves skeleton from estrogen-deficiency **bone loss** independently of changes in parathyroid function)

L19 ANSWER 16 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1994:290331 HCAPLUS
DOCUMENT NUMBER: 120:290331
TITLE: Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats: inhibition of indices of formation and resorption
AUTHOR(S): Turner, Russell T.; Evans, Glenda L.; Wakley, Glenn K.
CORPORATE SOURCE: Dep. Orthop. Surg., Mayo Found., Rochester, MN, USA
SOURCE: J. Bone Miner. Res. (1993), 8(3), 359-66
CODEN: JBMREJ; ISSN: 0884-0431
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Ovariectomy results in cancellous osteopenia in rat long bones, a condition that is prevented by treatment with estrogens. The purpose of these studies was to clarify the effects of estrogen on cancellous bone turnover using dynamic bone histomorphometry. Treatment of ovariectomized rats with DES reduced the mineral apposition rate, double-label perimeter, osteoblast no., suggesting that the hormone had inhibitiory effects on bone formation as well as bone resorption. However, the authors could not est. the bone formation rate because of rapid resorption of tetracycline-labeled bone in the ovariectomized rat. The magnitude of loss was documented by a time course study: 58% of the tetracycline initially incorporated into the secondary spongiosa of the tibial metaphysis was resorbed after 11 days and 89% was resorbed after 22 days. Similarly, cancellous bone area was decreased by 67% after 11 days and by 88% after 22 days. Administration of either DES or tamoxifen (TAM) dramatically reduced resorption of tetracycline as well as the decrease in cancellous bone area. These results demonstrate that (1) estrogen prevents osteopenia in ovariectomized (OVX) rats, in part by inhibiting

bone turnover, (2) TAM is an estrogen agonist on bone resorption, and (3) resorption of tetracycline-labeled bone leads to serious underestimation of the bone formation rate in OVX rats.

IT **56-53-1**, Diethylstilbesterol **10540-29-1**, Tamoxifen
RL: BIOL (Biological study)
(**bone loss** prevention by, after ovariectomy)

L19 ANSWER 17 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1993:254532 HCAPLUS
DOCUMENT NUMBER: 118:254532
TITLE: Preparation of triphenylethylene derivatives as antitumor agents and for treatment of osteoporosis
INVENTOR(S): Kouji, Hiroyuki; Ando, Satoshi
PATENT ASSIGNEE(S): Asahi Kasei Kogyo K. K., Japan
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9219585	A1	19921112	WO 1992-JP570	19920430
W: AU, CA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
JP 04330043	A2	19921118	JP 1991-124583	19910430
JP 04330071	A2	19921118	JP 1991-124584	19910430
JP 04356447	A2	19921210	JP 1991-156268	19910531
JP 05017424	A2	19930126	JP 1991-189495	19910704
JP 05039250	A2	19930219	JP 1991-219377	19910806
JP 05043522	A2	19930223	JP 1991-226419	19910813
JP 05112511	A2	19930507	JP 1991-296641	19911017
CA 2109426	AA	19921031	CA 1992-2109426	19920430
AU 9217402	A1	19921221	AU 1992-17402	19920430
AU 659157	B2	19950511		
EP 589039	A1	19940330	EP 1992-908856	19920430
R: CH, DE, ES, FR, GB, IT, LI				

PRIORITY APPLN. INFO.:

JP 1991-124583	19910430
JP 1991-124584	19910430
JP 1991-156268	19910531
JP 1991-189495	19910704
JP 1991-219377	19910806
JP 1991-226419	19910813
JP 1991-296641	19911017
WO 1992-JP570	19920430

OTHER SOURCE(S): MARPAT 118:254532
GI

[redacted]



I

AB Triphenylalkylene derivs. [I; R1 = CH2CH(OR8)CH2NR6R7, CH(CH2NR6R7)2, CH2CH2NR6R7; R6, R7 = H, (cyclo)alkyl, or NR6R7 = heterocyclyl optionally contg. heteroatoms, provided that R6 = R7 .noteq. H; R8 = H, alkylcarbonyl; R2 = (cyclo)alkyl; R3 = Ph, 3,4-methylenedioxyphenyl, provided that R3 = Ph, R1 .noteq. CH2CH2NR6R7; R4 = H, OH, R9CO2, R10OCH2O, OP(O)(OH)2, CH:NOR11; R9 = alkyl; R10 = alkyl, alkylcarbonyl; R5 = H, CH:NOR11; R11 = H, alkyl, phenylalkyl, alkoxycarbonylalkyl], having strong anti-estrogen activity and useful for the treatment of hormone-dependent breast cancer, are prepd. Thus, olefination of 4,4'-dihydroxybenzophenone with 3,4-methylenedioxypropiophenone in the presence of TiCl4 and Zn in THF to give 1,1-bis(4-hydroxyphenyl)-2-(3,4-methylenedioxyphenyl)-1-butene followed by conversion into the K salt in 0.5N aq. NaOH and etherification with epibromohydrin in DMF gave 1-[4-(2,3-epoxypropoxy)phenyl]-1-(4-hydroxyphenyl)-2-(3,4-methylenedioxyphenyl)-1-butene which was aminated with 50% aq. Me2NH in EtOH to give (E,Z)-I (R1 = CH2CH(OH)CH2NMe2, R2 = Et, R3 = 3,4-methylenedioxyphenyl, R4 = OH, R5 = H) (II). II at 1 .mu.g/day i.p. inhibited estradiol-induced uterine wt. increase in rats by 56.6%, vs. 5.8% for tamoxifen.

IT **103545-15-9P 147322-26-7P 147322-27-8P**
147322-31-4P 147322-32-5P 147322-33-6P
147322-40-5P 147322-41-6P 147322-42-7P
147322-43-8P 147322-44-9P 147322-45-0P
147322-46-1P 147322-53-0P 147322-54-1P
147322-57-4P 147322-58-5P 147322-59-6P
147322-60-9P 147322-61-0P 147322-64-3P
147322-65-4P 147322-66-5P 147322-67-6P
147322-68-7P 147322-69-8P 147322-70-1P
147322-71-2P 147322-72-3P 147322-73-4P
147322-74-5P 147322-75-6P 147322-76-7P
147322-83-6P 147322-84-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antitumor agent and for treatment of **osteoporosis**)

IT **68684-63-9P 91221-46-4P 147308-12-1P**
147308-13-2P 147322-98-3P 147322-99-4P
147323-02-2P 147323-03-3P 147323-04-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for antitumor and anti-**osteoporosis** triphenylalkylene)

L19 ANSWER 18 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:605220 HCAPLUS

DOCUMENT NUMBER: 117:205220
TITLE: Treatment of osteoporosis with phosphonates and estrogens
INVENTOR(S): McOsker, Jocelyn Elaine
PATENT ASSIGNEE(S): Norwich Eaton Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9214474	A1	19920903	WO 1992-US854	19920131
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
CA 2101275	AA	19920827	CA 1992-2101275	19920131
CA 2101275	C	19980804		
AU 9216433	A1	19920915	AU 1992-16433	19920131
AU 664368	B2	19951116		
EP 573604	A1	19931215	EP 1992-908494	19920131
EP 573604	B1	19950315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL				
JP 06505501	T2	19940623	JP 1992-511584	19920131
HU 66429	A2	19941128	HU 1993-2407	19920131
HU 215124	B	19980928		
AT 119777	E	19950415	AT 1992-908494	19920131
ES 2069424	T3	19950501	ES 1992-908494	19920131
CZ 282609	B6	19970813	CZ 1993-1755	19920131
RU 2113848	C1	19980627	RU 1993-54017	19920131
NO 9303044	A	19930826	NO 1993-3044	19930826

PRIORITY APPLN. INFO.: US 1991-661777 A 19910226
WO 1992-US854 A 19920131

OTHER SOURCE(S): MARPAT 117:205220

AB Osteoporosis is treated in humans or animals with a bone-active phosphonate, esp. a bisphosphonate or a phosphonoalkylphosphonate [.gtoreq.0.1 LED (least ED)/day] and an estrogen (.gtoreq.0.2-0.8 LED/day). Thus, a woman with postmenopausal osteoporosis was treated daily for 1 yr with 2-(3-pyridyl)-1-hydroxyethane-1,1-bisphosphonic acid (15 mg in a tablet) and 17.beta.-estradiol (0.03 mg from a transdermal patch).

IT **56-53-1**, Diethylstilbestrol **569-57-3**, Chlorotrianisene
RL: BIOL (Biological study)
(**osteoporosis** treatment with phosphonate deriv. and)

L19 ANSWER 19 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:490313 HCAPLUS
DOCUMENT NUMBER: 117:90313
TITLE: Preparation of prazosin analogs
INVENTOR(S): Pitha, Josef; Kusiak, John W.
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: U.S., 13 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5110927	A	19920505	US 1987-140744	19871231

OTHER SOURCE(S): MARPAT 117:90313
GI



I

AB Title compds. I [R = 1-imidazolylcarbonyl, COCH2Br, (substituted) cinnamoyl, PhNHC(:S), bicyclo[2.2.2]octa-2,5-dien-2-ylcarbonyl, bicyclo[2.2.2]oct-2-en-2-ylcarbonyl, etc.] were prepd. as antihypertensives. Thus, 1,3-cyclohexadiene underwent Diels-Alder cyclization with HC.tplbond.CCO2H to give bicyclo[2.2.2]octa-2,5-diene-2-carboxylic acid. This was converted to the acid chloride then treated with 4-amino-6,7-dimethoxy-2-(piperazin-1-yl)quinazoline to give title compd. I [R = bicyclo[2.2.2]octa-2,5-dien-2-ylcarbonyl] (II). For rats treated with II (0.09 mg/kg i.v.) or prazosin (0.11 mg/kg i.v.), the ones treated with II needed higher doses of phenylephrine to obtain increase in blood pressure.

IT **119809-77-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as **antihypertensive**)

L19 ANSWER 20 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:463786 HCAPLUS
DOCUMENT NUMBER: 117:63786
TITLE: Bone growth factors and inhibitors of bone resorption for promoting bone formation
INVENTOR(S): Adams, Steven W.; Armstrong, Rosa; Rosen, David
PATENT ASSIGNEE(S): Celtrix Pharmaceuticals, Inc., USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5118667	A	19920602	US 1991-695310	19910503
CA 2102429	AA	19921104	CA 1992-2102429	19920501
WO 9219262	A1	19921112	WO 1992-US3600	19920501
W: AU, CA, JP				
AU 9218913	A1	19921221	AU 1992-18913	19920501
AU 660182	B2	19950615		
JP 06511233	T2	19941215	JP 1992-510956	19920501

EP 514720 A2 19921125 EP 1992-107773 19920508
EP 514720 A3 19930303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1991-695310 19910503
WO 1992-US3600 19920501

AB Bone growth factors are used to stimulate new bone formation when administered with agents that inhibit bone resorption. Treatment of ovariectomized rats with transforming growth factor-.beta. resulted in increased bone formation. This was enhanced by concomitant treatment with estrogen.

IT **10540-29-1**, Tamoxifen
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(bone formation promotion by bone growth factors and, as **bone resorption** inhibitor)

L19 ANSWER 21 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:248381 HCAPLUS
DOCUMENT NUMBER: 116:248381
TITLE: Tamoxifen prevents bone loss in ovariectomized mice
AUTHOR(S): Broulik, P. D.
CORPORATE SOURCE: Fac. Med., Charles Univ., Prague, 128 21, Czech.
SOURCE: Endocr. Regul. (1991), 25(4), 217-19
CODEN: EREGE3
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Bone d. and mineral content of the femora were decreased in ovariectomized mice compared with intact control animals. Tamoxifen treated ovariectomized mice did not develop a decrease either in the bone d. or in calcium and phosphate content of the femora which were obsd. in ovariectomized mice. In addn., the wt. of uterus in tamoxifen-treated ovariectomized mice was the same as in intact controls. Thus, tamoxifen administered in vivo prevented the loss of bone mineral and uterus wt. in ovariectomized mice and thus showing true estrogen like activity.

IT **10540-29-1**, Tamoxifen
RL: BIOL (Biological study)
(**bone loss** from overiectomy prevention by)

L19 ANSWER 22 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:83664 HCAPLUS
DOCUMENT NUMBER: 116:83664
TITLE: Preparation of 5,6,7,8-tetrahydro-4H-thiazolo[5,4-b]azepine derivatives as antihypertensives
INVENTOR(S): Aono, Tetsuya; Shimamoto, Norio
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 63 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03206042	A2	19910909	JP 1990-833	19900106

OTHER SOURCE(S): MARPAT 116:83664
GI



I

AB The title compds. [I; R1 = H, (un)substituted aliph., acyl or sulfonyl; R2 = H, (un)substituted arom. or aliph.] are prepd. as K channel opener. Thus, 14.8 g 1,1'-carbonyldiimidazole was added to a soln. of 12 g 2,6-F2C6H3CO2H in THF and thereto after stirring 15 min at room temp. 9.73 g 3-amino-.epsilon.-caprolactam was added and the mixt. was stirred 5 h at room temp. to give 13.5 g 3-(2,6-difluorobenzoylamino)-.epsilon.-caprolactam which (8.96 g) was refluxed 24 h, with 8.96 g P4S10 in pyridine to give 23.8% I (R1 = H, R2 = 2,6-F2C6H3)(II). II and I [R1 = H, R2 = (Z)-4-Et2NC6H4CH:CH] (III) in vitro inhibited 8 and 100%, resp., rat aorta contraction induced by Et3NCl and BaCl2 and gave no inhibition of the one induced by 80 mM KCl. II and III at 1 mg/kg i.v. lowered 49 and 46%, resp. the blood pressure of rats. A total of 175 I were prepd.

IT **128068-06-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sulfuration-cyclization of, **antihypertensive** tetrahydrothiazoloazepine deriv. from)

IT **128068-59-7P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as **antihypertensive**)

L19 ANSWER 23 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:76566 HCAPLUS
DOCUMENT NUMBER: 116:76566
TITLE: A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat
AUTHOR(S): Kalu, D. N.; Salerno, E.; Liu, C. C.; Echon, R.; Ray, M.; Garza-Zapata, M.; Hollis, B. W.
CORPORATE SOURCE: Health Sci. Cent., Univ. Texas, San Antonio, TX, 78284-7756, USA
SOURCE: Bone Miner. (1991), 15(2), 109-23
CODEN: BOMIET; ISSN: 0169-6009
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This study was undertaken to examine the sep. and combined effects of tamoxifen (T), estrogen (E2), and progesterone (P) treatment on ovariectomized (Ooph) rats. The animals were treated for 40 days. Ovariectomy reduced cancellous bone vol. at the proximal tibia by 50%. Estradiol treatment completely prevented the bone loss and further increased bone vol. 77% over the level for the control group. Tamoxifen also prevented the ovariectomy-induced bone loss, but reduced the increase in cancellous bone induced by estradiol. In the ovariectomized rats, cancellous bone apposition rate increased 23%. This increase was suppressed 63% by estradiol, and only 18% by tamoxifen. Tamoxifen suppressed the inhibitory effect of estradiol on cancellous bone appositon rate. In contrast, the effect of progesterone treatment was only marginal. These findings indicate that the action of tamoxifen on bone is influenced by the ambient level of circulating estradiol, such that in estrogen deficiency, tamoxifen has a weak estrogen against action on bone, and in the presence of estrogen it has antiestrogen actions, with the dose

level and mode of administration employed. These conclusions have implications for the use of tamoxifen in the treatment of pre- and postmenopausal women.

IT **10540-29-1**, Tamoxifen
RL: BIOL (Biological study)
(**bone loss** inhibition by, estradiol effect on)

L19 ANSWER 24 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1991:536564 HCAPLUS
DOCUMENT NUMBER: 115:136564
TITLE: Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines
AUTHOR(S): Francis, John E.; Webb, Randy L.; Ghai, Geetha R.; Hutchison, Alan J.; Moskal, Michael A.; DeJesus, Reynalda; Yokoyama, Rina; Rovinski, Stephen L.; Contardo, Nicolina; et al.
CORPORATE SOURCE: Pharm. Div., Ciba-Geigy Corp., Summit, NJ, 07901, USA
SOURCE: J. Med. Chem. (1991), 34(8), 2570-9
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A wide variety of 2-substituted aminoadenosines were prepd. for comparison with the moderately A2 receptor selective adenosine agonist 2-anilinoadenosine. High selectivity combined with significant affinity at the A2 receptor in rat membranes was obsd. for those amines bearing a two-carbon chain to which was attached an aryl, heteroaryl, or alicyclic moiety. 2-(2-Phenethylamino)adenosine, a 14-fold A2 selective compd., was modified by introduction of a variety of substituents in the benzene ring and the side chain. Some of these changes led to improved A2 affinity and increased selectivity. Replacement of the Ph moiety by cyclohexenyl produced a 210-fold selective agonist I (R = cyclohexyl) whereas the cyclohexyl analog I (R = 1-cyclohexen-1-yl) was 530-fold selective at the A2 site. These compds. showed hypotensive activity in rat models over a range of doses without the bradycardia obsd. with less selective agonists.

IT **124498-89-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., adenosine receptor agonist, and **antihypertensive** activity of)

L19 ANSWER 25 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1990:545496 HCAPLUS

DOCUMENT NUMBER: 113:145496
TITLE: The relation between serum growth hormone and estradiol levels and osteoporosis in postmenopausal women
AUTHOR(S): Li, Guohua; Zeng, Meizhen
CORPORATE SOURCE: Coll. Med., Jinan Univ., Guangzhou, Peop. Rep. China
SOURCE: Zhonghua Yixue Zazhi (1990), 70(1), 16-19
CODEN: CHHTAT; ISSN: 0300-2578
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB Serum growth hormone (GH), estradiol (E2), FSH, LH, alk. phosphatase, and Ca levels, bone mass, and urinary Ca/creatinine ratio were detd. in postmenopausal women and compared with those in fertile women. The postmenopausal women had reduced serum levels of GH and E2 and bone mass and increased levels of serum FSH, LH, and alk. phosphatase and urinary Ca/creatinine ratio. The serum level of GH increased, whereas that of FSH, LH, and alk. phosphatase and urinary Ca/creatinine ratio were all decreased after di-Et stilbestrol treatment. Apparently, there is bone loss in early postmenopause and estrogen replacement therapy is necessary in postmenopausal women.

IT **56-53-1**, Diethyl stilbestrol
RL: BIOL (Biological study)
(alk. phosphatase and gonadotropins and growth hormone of blood serum and calcium of urine response to, in postmenopausal women, **osteoporosis** in relation to)

L19 ANSWER 26 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1990:526731 HCAPLUS
DOCUMENT NUMBER: 113:126731
TITLE: Hypotensive effects on spontaneously hypertensive rats and antifungal activity on various species of Fusarium oxysporum of diethylstilbestrol-related compounds
AUTHOR(S): Inamori, Yoshihiko; Ogawa, Masafumi; Amino, Hisako; Tsuboi, Mariko; Yamaguchi, Satomi; Tsujibo, Hiroshi; Takemura, Shoji
CORPORATE SOURCE: Osaka Univ. Pharm. Sci., Matsubara, 580, Japan
SOURCE: Chem. Pharm. Bull. (1990), 38(7), 2045-6
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **56-53-1**, Diethylstilbestrol
RL: BIOL (Biological study)
(antifungal and **antihypertensive** activities of)

L19 ANSWER 27 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1990:400561 HCAPLUS
DOCUMENT NUMBER: 113:561
TITLE: Antiestrogens and their use in treatment of menopause and osteoporosis
INVENTOR(S): Young, Ronald L.
PATENT ASSIGNEE(S): BCM Technologies, Inc., USA
SOURCE: U.S., 10 pp. Cont.-in-part of U.S. 4,729,999.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4894373	A	19900116	US 1988-143081	19880112
US 4729999	A	19880308	US 1984-660510	19841012
JP 61178917	A2	19860811	JP 1985-226022	19851012
JP 06080017	B4	19941012		

PRIORITY APPLN. INFO.: US 1984-660510 19841012
OTHER SOURCE(S): MARPAT 113:561
IT **50-41-9 911-45-5**, Clomiphene **5863-35-4**
10448-84-7 10540-29-1, Tamoxifen **54965-24-1**
56287-31-1, CI-680
RL: BIOL (Biological study)
(estrogen deficiency in menopause and **osteoporosis** treatment with)

L19 ANSWER 28 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1990:119353 HCAPLUS
DOCUMENT NUMBER: 112:119353
TITLE: Preparation of 2-substituted adenosine derivatives as antihypertensive and antiatherosclerotic agents and pharmaceutical compositions containing them
INVENTOR(S): Hutchison, Alan J.; Francis, John E.
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 323807	A2	19890712	EP 1988-810900	19881229
EP 323807	A3	19900620		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5034381	A	19910723	US 1988-193968	19880513
NO 8805821	A	19890710	NO 1988-5821	19881230
NO 169843	B	19920504		
NO 169843	C	19920812		
FI 8900028	A	19890708	FI 1989-28	19890104
FI 90430	B	19931029		
FI 90430	C	19940210		
HU 48904	A2	19890728	HU 1989-33	19890105
HU 202550	B	19910328		
ZA 8900084	A	19890830	ZA 1989-84	19890105
DD 283402	A5	19901010	DD 1989-324859	19890105
CA 1325209	A1	19931214	CA 1989-587534	19890105
DK 8900050	A	19890708	DK 1989-50	19890106
AU 8927767	A1	19890713	AU 1989-27767	19890106
AU 618055	B2	19911212		
JP 01265100	A2	19891023	JP 1989-590	19890106

PRIORITY APPLN. INFO.: US 1988-142055 19880107
US 1988-193968 19880513

IT **124499-27-0P 124499-28-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, in prepn. of **antihypertensives** and antiatherosclerotics)

IT **124498-89-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as **antihypertensive** and antiatherosclerotic)

L19 ANSWER 29 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1989:508829 HCAPLUS
DOCUMENT NUMBER: 111:108829
TITLE: Effects of two inhibitors of anion transport on bone resorption in organ culture
AUTHOR(S): Klein-Nulend, Jenneke; Raisz, Lawrence G.
CORPORATE SOURCE: Health Cent., Univ. Connecticut, Farmington, CT, 06032, USA
SOURCE: Endocrinology (Baltimore) (1989), 125(2), 1019-24
CODEN: ENDOAO; ISSN: 0013-7227
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **51023-76-8**, SITS **53005-05-3**, DIDS
RL: BIOL (Biological study)
(**bone resorption** inhibition by, calcium and parathormone in)

L19 ANSWER 30 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1988:622782 HCAPLUS
DOCUMENT NUMBER: 109:222782
TITLE: Neonatal diethylstilbestrol alters blood pressure and CNS drinking response in SHR and WKY rats
AUTHOR(S): Lamartiniere, C. A.; Pearson, A. T.; Rockhold, R. W.
CORPORATE SOURCE: Dep. Environ. Health Sci., Univ. Alabama, Birmingham, AL, 35294, USA
SOURCE: Clin. Exp. Hypertens., Part A (1988), A10(5), 843-57
CODEN: CEHADM; ISSN: 0730-0077
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **56-53-1**, Diethylstilbestrol
RL: BIOL (Biological study)
(**blood pressure** and water drinking responses to neonatal administration of)

L19 ANSWER 31 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1988:529008 HCAPLUS
DOCUMENT NUMBER: 109:129008
TITLE: Preparation of angiotensin II receptor-blocking (phenylalkyl)imidazoles
INVENTOR(S): Carini, David John; Duncia, John Jonas Vytautas
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: Eur. Pat. Appl., 314 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 253310	A2	19880120	EP 1987-109919	19870709
EP 253310	A3	19900829		
EP 253310	B1	19941026		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 1334092	A1	19950124	CA 1987-540399	19870623

NO 8702863	A	19880112	NO 1987-2863	19870709
NO 176049	B	19941017		
NO 176049	C	19950125		
ES 2063734	T3	19950116	ES 1987-109919	19870709
DK 8703596	A	19880112	DK 1987-3596	19870710
FI 8703071	A	19880112	FI 1987-3071	19870710
FI 96025	B	19960115		
FI 96025	C	19960425		
AU 8775596	A1	19880121	AU 1987-75596	19870710
AU 599396	B2	19900719		
JP 63023868	A2	19880201	JP 1987-171328	19870710
JP 05029351	B4	19930430		
HU 45976	A2	19880928	HU 1987-3174	19870710
ZA 8705052	A	19890329	ZA 1987-5052	19870710
SU 1694062	A3	19911123	SU 1987-4203085	19870710
IL 83153	A1	19911215	IL 1987-83153	19870710
US 5128355	A	19920707	US 1989-435869	19891113
US 5153197	A	19921006	US 1989-436165	19891113
US 5155118	A	19921013	US 1989-436281	19891113

PRIORITY APPLN. INFO.:

US 1986-884920	A	19860711
US 1987-50341	A	19870522
US 1988-142580	B2	19880107
US 1988-279194	A3	19881206

OTHER SOURCE(S): MARPAT 109:129008

IT **114773-12-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, in prepn. of **antihypertensives**)

IT **114799-60-9P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as **antihypertensive**)

L19 ANSWER 32 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1988:473432 HCAPLUS
DOCUMENT NUMBER: 109:73432
TITLE: Preparation of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acids and analogs as antihypertensives
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 58 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62240683	A2	19871021	JP 1987-76534	19870331
JP 2506105	B2	19960612		
US 4812462	A	19890314	US 1986-847067	19860401
EP 245637	A1	19871119	EP 1987-104736	19870331
EP 245637	B1	19911016		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 68495	E	19911115	AT 1987-104736	19870331
ES 2038613	T3	19930801	ES 1987-104736	19870331
US 4816463	A	19890328	US 1987-35521	19870407
JP 08208652	A2	19960813	JP 1995-313683	19951108

JP 2648793 B2 19970903
PRIORITY APPLN. INFO.: US 1986-847067 19860401
EP 1987-104736 19870331
OTHER SOURCE(S): CASREACT 109:73432
IT **114787-47-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as **antihypertensive**)

L19 ANSWER 33 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1988:454470 HCAPLUS
DOCUMENT NUMBER: 109:54470
TITLE: Aminoalkyl derivatives of cis- and trans-stilbenes, useful in the treatment of angina and hypertension, and a process for their preparation
INVENTOR(S): Carson, John Robert
PATENT ASSIGNEE(S): McNeilab, Inc., USA
SOURCE: Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 250254	A1	19871223	EP 1987-305453	19870619
EP 250254	B1	19910619		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 63022547	A2	19880130	JP 1987-150356	19870618
ZA 8704448	A	19890222	ZA 1987-4448	19870618
DK 8703155	A	19871221	DK 1987-3155	19870619
AU 8774534	A1	19871224	AU 1987-74534	19870619
AT 64591	E	19910715	AT 1987-305453	19870619
AU 9176375	A1	19910808	AU 1991-76375	19910503

PRIORITY APPLN. INFO.: US 1986-876628 19860620
EP 1987-305453 19870619

IT **115198-25-9P 115198-26-0P 115198-27-1P**
115198-28-2P 115198-29-3P 115198-30-6P
115198-31-7P 115198-32-8P 115198-33-9P
115198-34-0P 115198-35-1P 115198-36-2P
115198-37-3P 115198-38-4P 115198-39-5P
115198-40-8P 115198-41-9P 115198-42-0P
115198-43-1P 115198-44-2P 115198-45-3P
115198-46-4P 115198-47-5P 115198-48-6P
115198-49-7P 115198-50-0P 115198-51-1P
115198-52-2P 115198-53-3P 115198-54-4P
115198-55-5P 115216-66-5P 115216-67-6P
115466-00-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antianginal and **antihypertensive**)

L19 ANSWER 34 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1988:143689 HCAPLUS
DOCUMENT NUMBER: 108:143689
TITLE: Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats
AUTHOR(S): Turner, Russell T.; Wakley, Glenn K.; Hannon, Kathleen

S.; Bell, Norman H.
CORPORATE SOURCE: Dep. Physiol. Pharmacol., Loma Linda Univ., Loma Linda, CA, 92354, USA
SOURCE: Endocrinology (Baltimore) (1988), 122(3), 1146-50
CODEN: ENDOAO; ISSN: 0013-7227
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **10540-29-1**, Tamoxifen
RL: BIOL (Biological study)
(osteoclast-mediated **bone resorption** inhibition by)

L19 ANSWER 35 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1988:107682 HCAPLUS
DOCUMENT NUMBER: 108:107682
TITLE: Effects of vanadate on vascular smooth muscles of WKY and SHRSP
AUTHOR(S): Sunano, Satoru; Shimada, Tomoko; Shimamura, Keiichi
CORPORATE SOURCE: Inst. Hypertension, Kinki Univ., Osaka, Japan
SOURCE: Jpn. Heart J. (1987), 28(5), 765-81
CODEN: JHEJAR; ISSN: 0021-4868
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **53005-05-3**, DIDS
RL: BIOL (Biological study)
(vanadate-induced contraction of vascular smooth muscle response to, **hypertensive** strain in relation to)

L19 ANSWER 36 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1988:69162 HCAPLUS
DOCUMENT NUMBER: 108:69162
TITLE: Effects of anti-estrogens on bone in castrated and intact female rats
AUTHOR(S): Jordan, V. Craig; Phelps, Erik; Lindgren, J. Urban
CORPORATE SOURCE: Clin. Cancer Cent., Univ. Wisconsin, Madison, WI, 53792, USA
SOURCE: Breast Cancer Res. Treat. (1987), 10(1), 31-5
CODEN: BCTRD6; ISSN: 0167-6806
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **10540-29-1**, Tamoxifen
RL: BIOL (Biological study)
(**bone loss** inhibition by, after ovariectomy)

L19 ANSWER 37 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1986:583914 HCAPLUS
DOCUMENT NUMBER: 105:183914
TITLE: Inhibition of cholesterol and fatty acid synthesis in rats by an estrogen antagonist both in isolated hepatocytes and in vivo
AUTHOR(S): McCune, Sylvia A.; Rimmell, Frank; Hoversland, Roger C.; Jurin, Richard R.
CORPORATE SOURCE: Chicago Med. Sch., Univ. Health Sci., North Chicago, IL, 60064, USA
SOURCE: Biochem. Soc. Trans. (1986), 14(6), 1198
CODEN: BCSTB5; ISSN: 0300-5127
DOCUMENT TYPE: Journal
LANGUAGE: English

L19 ANSWER 38 OF 56 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1986:207168 HCAPLUS
DOCUMENT NUMBER: 104:207168
TITLE: 1,4-Dihydropyridine derivatives and pharmaceutical compositions comprising them
INVENTOR(S): Kutsuma, Teruo; Ikawa, Hiroshi; Sato, Yoshiaki
PATENT ASSIGNEE(S): Fujirebio, Inc., Japan
SOURCE: Eur. Pat. Appl., 67 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 161877	A2	19851121	EP 1985-303141	19850502
EP 161877	A3	19870729		
EP 161877	B1	19910529		
R: CH, DE, FR, GB, IT, LI, NL				
JP 60233058	A2	19851119	JP 1984-88411	19840504
JP 03014307	B4	19910226		
JP 61007255	A2	19860113	JP 1984-125379	19840620
JP 06029245	B4	19940420		
US 4672068	A	19870609	US 1985-727692	19850426
JP 01025758	A2	19890127	JP 1988-169086	19880708

PRIORITY APPLN. INFO.: JP 1984-88411 19840504
JP 1984-125379 19840620

OTHER SOURCE(S): CASREACT 104:207168

IT **102106-41-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as **antihypertensive**)

L19 ANSWER 39 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1986:129927 HCAPLUS
DOCUMENT NUMBER: 104:129927
TITLE: Piperazine derivatives
INVENTOR(S): Komoto, Teruo; Sato, Susumu; Ogawa, Yoichiro; Isomae, Kazuo; Katori, Tatsuhiko
PATENT ASSIGNEE(S): S. S. Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60204763	A2	19851016	JP 1984-61517	19840329

IT **100982-50-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as vasodilator and **antihypertensive**)

L19 ANSWER 40 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1986:45971 HCAPLUS
DOCUMENT NUMBER: 104:45971
TITLE: Effects of the antiestrogens tamoxifen and clomiphene

on bone resorption in vitro
AUTHOR(S): Stewart, Pamela J.; Stern, Paula H.
CORPORATE SOURCE: Med. Dent. Sch., Northwest. Univ., Chicago, IL, 60611, USA
SOURCE: Endocrinology (Baltimore) (1986), 118(1), 125-31
CODEN: ENDOAO; ISSN: 0013-7227
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **911-45-5 10540-29-1**
RL: BIOL (Biological study)
(**bone resorption** inhibition by)

L19 ANSWER 41 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1985:426532 HCAPLUS
DOCUMENT NUMBER: 103:26532
TITLE: Lead exposure and changes in the renin-angiotensin-aldosterone system in man
AUTHOR(S): Campbell, B. C.; Meredith, P. A.; Scott, J. J. C.
CORPORATE SOURCE: Stobhill Gen. Hosp., Univ. Glasgow, Glasgow, G21 3UW, UK
SOURCE: Toxicol. Lett. (1985), 25(1), 25-32
CODEN: TOLED5; ISSN: 0378-4274
DOCUMENT TYPE: Journal
LANGUAGE: English

L19 ANSWER 42 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1983:46935 HCAPLUS
DOCUMENT NUMBER: 98:46935
TITLE: Chloroquine, hydroxystilbamidine, and dapsone inhibit resorption of fetal rat bone in organ culture
AUTHOR(S): Eilon, Gabriel; Raisz, Lawrence G.
CORPORATE SOURCE: Health Cent., Univ. Connecticut, Farmington, CT, 06032, USA
SOURCE: Calcif. Tissue Int. (1982), 34(5), 506-9
CODEN: CTINDZ; ISSN: 0171-967X
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **495-99-8**
RL: BIOL (Biological study)
(**bone resorption** inhibition by)

L19 ANSWER 43 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1980:561754 HCAPLUS
DOCUMENT NUMBER: 93:161754
TITLE: Vascular action of high dose estrogen in rats
AUTHOR(S): Kondo, Kazuoki; Okuno, Tetsuji; Eguchi, Toyohisa; Yasui, Toshiyuki; Suzuki, Hiromichi; Nagahama, Shusaku; Saruta, Takao
CORPORATE SOURCE: Sch. Med., Keio Univ., Tokyo, 160, Japan
SOURCE: Endocrinol. Jpn. (1980), 27(3), 307-13
CODEN: ECJPAE; ISSN: 0013-7219
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **522-40-7**
RL: BIOL (Biological study)
(artery contraction and **blood pressure** response to)

L19 ANSWER 44 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1980:195361 HCAPLUS

DOCUMENT NUMBER: 92:195361
TITLE: Influence of adult age on the skeletal response to phosphate and estrogen in rats
AUTHOR(S): Draper, H. H.; Bell, R. Raines; Shin, Keun S.
CORPORATE SOURCE: Dep. Food Sci., Univ. Illinois, Urbana, IL, 61801, USA
SOURCE: J. Nutr. (1980), 110(4), 778-83
CODEN: JONUAI; ISSN: 0022-3166
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **56-53-1**
RL: BIOL (Biological study)
(**bone resorption** response to, in senescence, dietary phosphate in relation to)

L19 ANSWER 45 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1980:158238 HCAPLUS
DOCUMENT NUMBER: 92:158238
TITLE: Hypertension and sex hormones
AUTHOR(S): Saruda, Akio
CORPORATE SOURCE: Med. Sch., Keio Univ., Tokyo, Japan
SOURCE: Kawaguchiko Kanferansu (1978), 12(Koketsuatsu to Horumon), 149-64
CODEN: KAKNDY
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
IT **56-53-1**
RL: BIOL (Biological study)
(**blood pressure** and angiotensin-renin system response to, contraceptive activity in relation to)

L19 ANSWER 46 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1979:16821 HCAPLUS
DOCUMENT NUMBER: 90:16821
TITLE: Effect of estrogen upon the juxtaglomerular apparatus and the renin-angiotensin system in rats
AUTHOR(S): Kondo, Kazuoki; Misumi, Jiro; Nakamura, Ryuichi; Saito, Ikuo; Saruta, Takao
CORPORATE SOURCE: Dep. Intern. Med., Univ. Keio Sch. Med., Tokyo, Japan
SOURCE: Tohoku J. Exp. Med. (1978), 126(3), 267-72
CODEN: TJEMAO; ISSN: 0040-8727
DOCUMENT TYPE: Journal
LANGUAGE: English

L19 ANSWER 47 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1979:16785 HCAPLUS
DOCUMENT NUMBER: 90:16785
TITLE: Effects of estrogenic hormones on uteroplacental hemodynamics and progesterone production in the sheep
AUTHOR(S): Assali, N. S.; Clark, K. E.; Zugaib, M.; Brinkman, C. R., III; Nuwayhid, B.
CORPORATE SOURCE: Sch. Med., Univ. California, Los Angeles, Calif., USA
SOURCE: Int. J. Fertil. (1978), 23(3), 219-23
CODEN: INJFA3; ISSN: 0020-725X
DOCUMENT TYPE: Journal
LANGUAGE: English

L19 ANSWER 48 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1979:16671 HCAPLUS
DOCUMENT NUMBER: 90:16671

TITLE: Relation of hemodynamics to the incidence of diethylstilbestrol-induced aortic ruptures in hypertensive and hypotensive lines of turkeys
AUTHOR(S): Simpson, Charles F.
CORPORATE SOURCE: Coll. Vet. Med., Univ. Florida, Gainesville, Fla., USA
SOURCE: Atherosclerosis (Shannon, Irel.) (1978), 30(4), 249-54
CODEN: ATHSBL; ISSN: 0021-9150
DOCUMENT TYPE: Journal
LANGUAGE: English

L19 ANSWER 49 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1976:428964 HCAPLUS
DOCUMENT NUMBER: 85:28964
TITLE: Changes in blood pressure and norepinephrine concentration following administration of estrogens to genetically hypertensive and normotensive rats
AUTHOR(S): Lew, G. M.
CORPORATE SOURCE: Dep. Anat., Michigan State Univ., East Lansing, Mich., USA
SOURCE: Gen. Pharmacol. (1975), 6(2-3), 121-5
CODEN: GEPHDP
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **56-53-1**
RL: BIOL (Biological study)
(norepinephrine of adrenal gland and heart response to, in **hypertension**)

L19 ANSWER 50 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1975:526645 HCAPLUS
DOCUMENT NUMBER: 83:126645
TITLE: Estrogen hypertension in rats
AUTHOR(S): Saruta, T.; Nakamura, R.; Saito, I.; Kondo, K.; Matuki, S.
CORPORATE SOURCE: Sch. Med., Univ. Keio, Tokyo, Japan
SOURCE: Clin. Sci. Mol. Med. (1975), 48(5), 457-60
CODEN: CSMMCA
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **316-23-4**
RL: BIOL (Biological study)
(**hypertension** from, plasma renin system in relation to)

L19 ANSWER 51 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1975:81082 HCAPLUS
DOCUMENT NUMBER: 82:81082
TITLE: Effect of estrogens and gestagens on exchangeable sodium
AUTHOR(S): Crane, Milton G.; Harris, J. J.
CORPORATE SOURCE: Dep. Intern. Med., Loma Linda Univ., Loma Linda, Calif., USA
SOURCE: Oral Contracept. High Blood Pressure, Proc. Symp. (1974), Meeting Date 1973, 159-69. Editor(s): Fregley, Melvin J; Fregley, Marilyn S. Dolphin Press: Gainesville, Fla.
CODEN: 29MKAF
DOCUMENT TYPE: Conference
LANGUAGE: English

L19 ANSWER 52 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1973:522020 HCAPLUS
DOCUMENT NUMBER: 79:122020
TITLE: Mechanism of estrogen hypertension
AUTHOR(S): Saruta, Takao; Ozawa, Yukio; Asano, Seiichi
CORPORATE SOURCE: Sch. Med., Keio Univ., Tokyo, Japan
SOURCE: Jap. Circ. J. (1972), 36(6), 611-16
CODEN: JCIRA2
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **316-23-4**
RL: BIOL (Biological study)
(**hypertension** from, renin-angiotensin system in relation to)

L19 ANSWER 53 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1970:421858 HCAPLUS
DOCUMENT NUMBER: 73:21858
TITLE: Effects of estrogens on pressor responses to angiotensin and renin
AUTHOR(S): Nasjletti, Alberto; Matsunaga, Masato; Masson, Georges M. C.
CORPORATE SOURCE: Res. Div., Cleveland Clin. Found., Cleveland, Ohio, USA
SOURCE: Proc. Soc. Exp. Biol. Med. (1970), 133(2), 407-9
CODEN: PSEBAA
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **56-53-1**
RL: BIOL (Biological study)
(angiotensin and renin effect on **blood pressure** in response to)

L19 ANSWER 54 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1970:97102 HCAPLUS
DOCUMENT NUMBER: 72:97102
TITLE: Modifications of the serum proteins and calcium, and of bone structure, in growing chickens treated with diethylstilbestrol and thyroxine
AUTHOR(S): Ballarini, Giovanni; Orlandini, I.; Ferrari, Angela
CORPORATE SOURCE: Ist. Clin. Med. Vet., Univ. Parma, Parma, Italy
SOURCE: Veterinaria (Milan) (1969), 18(5), 291-308
CODEN: VETEAS
DOCUMENT TYPE: Journal
LANGUAGE: Italian
IT **56-53-1**
RL: BIOL (Biological study)
(calcium and globulins of blood serum in response to, **osteoporosis** induction in relation to)

L19 ANSWER 55 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1970:87663 HCAPLUS
DOCUMENT NUMBER: 72:87663
TITLE: Aortic rupture, body weight, and blood pressure in the turkey as influenced by strain, dietary fat, beta-aminopropionitrile fumarate, and diethylstilbestrol
AUTHOR(S): Krista, L. M.; Waibel, P. E.; Sautter, J. H.; Shoffner, R. N.
CORPORATE SOURCE: Dep. of Anim. Sci., Univ. of Minnesota, St. Paul,

Minn., USA
SOURCE: Poultry Sci. (1969), 48(6), 1954-60
CODEN: POSCAL
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **56-53-1**
RL: BIOL (Biological study)
(aortic rupture and **blood pressure** of turkeys in response to)

L19 ANSWER 56 OF 56 HCAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1967:418252 HCAPLUS
DOCUMENT NUMBER: 67:18252
TITLE: Estrogens and postmenopausal osteoporosis
AUTHOR(S): Strandjord, Nels M.; Lanzl, Lawrence H.
CORPORATE SOURCE: Univ. of Chicago, Chicago, Ill., USA
SOURCE: NASA [Spec. Publ.] SP (1965), No. 64, 163-7
CODEN: NSSPAW
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **56-53-1**
RL: BIOL (Biological study)
(in **osteoporosis** (postmenopausal) prevention)

=>

=>

=> select hit rn l19 1-56
SELECT IS APPROXIMATELY 46% COMPLETE
SELECT IS APPROXIMATELY 55% COMPLETE
COMMAND INTERRUPTED

=>

=>

=> select hit rn l19 1-56
COMMAND INTERRUPTED
REENTER FILE 'HCAPLUS'
AND TRY AGAIN, OR ENTER '?' FOR MORE INFORMATION.

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:09:09 ON 19 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1947 - 19 Nov 2001 VOL 135 ISS 22
FILE LAST UPDATED: 18 Nov 2001 (20011118/ED)

This file contains CAS Registry Numbers for easy and accurate

substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> select hit rn l19 1-56
SELECT IS APPROXIMATELY 41% COMPLETE
SELECT IS APPROXIMATELY 44% COMPLETE
SELECT IS APPROXIMATELY 48% COMPLETE
SELECT IS APPROXIMATELY 50% COMPLETE
SELECT IS APPROXIMATELY 51% COMPLETE
SELECT IS APPROXIMATELY 57% COMPLETE
SELECT IS APPROXIMATELY 58% COMPLETE
SELECT IS APPROXIMATELY 69% COMPLETE
E18 THROUGH E136 ASSIGNED

=> fil reg
COST DISPLAY IS INCOMPLETE

	QUANTITY @	RATE	ESTIMATED COST U.S. DOLLARS
YOUR TOTAL SESSION COSTS ARE	0.99		427.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.70	-20.58

FILE 'REGISTRY' ENTERED AT 10:28:51 ON 19 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 17 NOV 2001 HIGHEST RN 370839-11-5
DICTIONARY FILE UPDATES: 17 NOV 2001 HIGHEST RN 370839-11-5

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d his 120

(FILE 'HCAPLUS' ENTERED AT 09:57:22 ON 19 NOV 2001)

FILE 'HCAPLUS' ENTERED AT 10:09:09 ON 19 NOV 2001
SELECT HIT RN L19 1-56

FILE 'REGISTRY' ENTERED AT 10:28:51 ON 19 NOV 2001
L20 119 S E18-E136

=>
=>

=> d reg l20 tot

1	RN	209684-38-8	REGISTRY
2	RN	209684-35-5	REGISTRY
3	RN	209684-33-3	REGISTRY
4	RN	209684-31-1	REGISTRY
5	RN	209684-29-7	REGISTRY
6	RN	209684-27-5	REGISTRY
7	RN	209684-24-2	REGISTRY
8	RN	209684-21-9	REGISTRY
9	RN	165813-04-7	REGISTRY
10	RN	165813-03-6	REGISTRY
11	RN	165813-02-5	REGISTRY
12	RN	165813-01-4	REGISTRY
13	RN	147323-04-4	REGISTRY
14	RN	147323-03-3	REGISTRY
15	RN	147323-02-2	REGISTRY
16	RN	147322-99-4	REGISTRY
17	RN	147322-98-3	REGISTRY
18	RN	147322-84-7	REGISTRY
19	RN	147322-83-6	REGISTRY
20	RN	147322-76-7	REGISTRY
21	RN	147322-75-6	REGISTRY
22	RN	147322-74-5	REGISTRY
23	RN	147322-73-4	REGISTRY
24	RN	147322-72-3	REGISTRY
25	RN	147322-71-2	REGISTRY
26	RN	147322-70-1	REGISTRY
27	RN	147322-69-8	REGISTRY
28	RN	147322-68-7	REGISTRY
29	RN	147322-67-6	REGISTRY
30	RN	147322-66-5	REGISTRY
31	RN	147322-65-4	REGISTRY
32	RN	147322-64-3	REGISTRY
33	RN	147322-61-0	REGISTRY
34	RN	147322-60-9	REGISTRY
35	RN	147322-59-6	REGISTRY
36	RN	147322-58-5	REGISTRY
37	RN	147322-57-4	REGISTRY
38	RN	147322-54-1	REGISTRY
39	RN	147322-53-0	REGISTRY
40	RN	147322-46-1	REGISTRY
41	RN	147322-45-0	REGISTRY
42	RN	147322-44-9	REGISTRY
43	RN	147322-43-8	REGISTRY
44	RN	147322-42-7	REGISTRY
45	RN	147322-41-6	REGISTRY
46	RN	147322-40-5	REGISTRY
47	RN	147322-33-6	REGISTRY
48	RN	147322-32-5	REGISTRY
49	RN	147322-31-4	REGISTRY
50	RN	147322-27-8	REGISTRY
51	RN	147322-26-7	REGISTRY

52 RN 147308-13-2 REGISTRY
53 RN 147308-12-1 REGISTRY
54 RN 128068-59-7 REGISTRY
55 RN 128068-06-4 REGISTRY
56 RN 124499-28-1 REGISTRY
57 RN 124499-27-0 REGISTRY
58 RN 124498-89-1 REGISTRY
59 RN 119809-77-7 REGISTRY
60 RN 116057-75-1 REGISTRY
61 RN 115466-00-7 REGISTRY
62 RN 115216-67-6 REGISTRY
63 RN 115216-66-5 REGISTRY
64 RN 115198-55-5 REGISTRY
65 RN 115198-54-4 REGISTRY
66 RN 115198-53-3 REGISTRY
67 RN 115198-52-2 REGISTRY
68 RN 115198-51-1 REGISTRY
69 RN 115198-50-0 REGISTRY
70 RN 115198-49-7 REGISTRY
71 RN 115198-48-6 REGISTRY
72 RN 115198-47-5 REGISTRY
73 RN 115198-46-4 REGISTRY
74 RN 115198-45-3 REGISTRY
75 RN 115198-44-2 REGISTRY
76 RN 115198-43-1 REGISTRY
77 RN 115198-42-0 REGISTRY
78 RN 115198-41-9 REGISTRY
79 RN 115198-40-8 REGISTRY
80 RN 115198-39-5 REGISTRY
81 RN 115198-38-4 REGISTRY
82 RN 115198-37-3 REGISTRY
83 RN 115198-36-2 REGISTRY
84 RN 115198-35-1 REGISTRY
85 RN 115198-34-0 REGISTRY
86 RN 115198-33-9 REGISTRY
87 RN 115198-32-8 REGISTRY
88 RN 115198-31-7 REGISTRY
89 RN 115198-30-6 REGISTRY
90 RN 115198-29-3 REGISTRY
91 RN 115198-28-2 REGISTRY
92 RN 115198-27-1 REGISTRY
93 RN 115198-26-0 REGISTRY
94 RN 115198-25-9 REGISTRY
95 RN 114799-60-9 REGISTRY
96 RN 114787-47-2 REGISTRY
97 RN 114773-12-5 REGISTRY
98 RN 103545-15-9 REGISTRY
99 RN 102106-41-2 REGISTRY
100 RN 100982-50-1 REGISTRY
101 RN 91221-46-4 REGISTRY
102 RN 82413-20-5 REGISTRY
103 RN 68684-63-9 REGISTRY
104 RN 56287-31-1 REGISTRY
105 RN 54965-24-1 REGISTRY
106 RN 53005-05-3 REGISTRY
107 RN 51023-76-8 REGISTRY
108 RN 15690-57-0 REGISTRY
DR 96189-16-1
109 RN 15690-55-8 REGISTRY

```
110       RN    10540-29-1  REGISTRY
111       RN    10448-84-7  REGISTRY
DR   35258-22-1
112       RN     5863-35-4  REGISTRY
DR   11126-33-3, 28794-69-6
113       RN      911-45-5  REGISTRY
114       RN      569-57-3  REGISTRY
DR   13003-83-3
115       RN      522-40-7  REGISTRY
DR   43049-99-6
116       RN      495-99-8  REGISTRY
117       RN      316-23-4  REGISTRY
118       RN       56-53-1  REGISTRY
DR   8026-45-7, 8028-09-9, 8030-34-0, 8049-42-1, 8053-00-7
119       RN       50-41-9  REGISTRY


=>
=>

=> d ide can l20 1 9 13 16 52 54 56 58 59 60 61 62 64 95 96 97 98 99 100 101 102
103 104 105 106 107 108 110 111 112 113 114 115 116 117 118 119


L20  ANSWER 1 OF 119  REGISTRY  COPYRIGHT 2001 ACS
RN   209684-38-8  REGISTRY
CN   Phenol, 3-[1-[4-[2-[ethyl(phenylmethyl)amino]ethoxy]phenyl]-2-phenyl-1-
     butenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI)  (CA
     INDEX NAME)
MF   C33 H35 N O2 . C6 H8 O7
SR   CA
LC   STN Files:   CA, CAPLUS, TOXLIT, USPATFULL

     CM   1

     CRN  209684-24-2
     CMF  C33 H35 N O2
```




```
     CM   2

     CRN  77-92-9
     CMF  C6 H8 O7
```



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:100036

L20 ANSWER 9 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **165813-04-7** REGISTRY
CN Phenol, 3-[1-[4-[2-(ethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H29 N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:100036

REFERENCE 2: 123:93335

L20 ANSWER 13 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **147323-04-4** REGISTRY
CN Benzaldehyde, 3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H29 N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:254532

L20 ANSWER 16 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **147322-99-4** REGISTRY
CN Oxirane, [[4-(1,2-diphenyl-1-butenyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H24 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:254532

L20 ANSWER 52 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **147308-13-2** REGISTRY
CN Phenol, 4-(1,2-diphenyl-1-butenyl)-, potassium salt (9CI) (CA INDEX NAME)
MF C22 H20 O . K
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
CRN (68684-63-9)



● K

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:254532

L20 ANSWER 54 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **128068-59-7** REGISTRY
CN 4H-Thiazolo[5,4-b]azepine, 2-(1,2-diphenylethenyl)-5,6,7,8-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)
MF C21 H20 N2 S . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



● HCl

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 116:83664

REFERENCE 2: 113:40664

L20 ANSWER 56 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **124499-28-1** REGISTRY
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[4-(2-phenylethenyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H19 N O2
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 115:136564

REFERENCE 2: 112:119353

L20 ANSWER 58 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **124498-89-1** REGISTRY
CN Adenosine, 2-[[2-[4-(2-phenylethenyl)phenyl]ethyl]amino]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H28 N6 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 115:136564

REFERENCE 2: 112:119353

L20 ANSWER 59 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **119809-77-7** REGISTRY
CN Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1-oxo-2,3-diphenyl-2-propenyl)- (9CI) (CA INDEX NAME)
MF C29 H29 N5 O3

SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 117:90313

REFERENCE 2: 110:154320

L20 ANSWER 60 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **116057-75-1** REGISTRY
CN Pyrrolidine, 1-[2-[4-[(1E)-1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyrrolidine, 1-[2-[4-[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]-, (E)-
OTHER NAMES:
CN CB 7432
CN Idoxifene
CN SB 223030
FS STEREOSEARCH
MF C28 H30 I N O
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

99 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
100 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:205530

REFERENCE 2: 135:205490

REFERENCE 3: 135:142233

REFERENCE 4: 135:132470

REFERENCE 5: 135:116436

REFERENCE 6: 135:86677

REFERENCE 7: 135:82051

REFERENCE 8: 135:71210

REFERENCE 9: 135:71043

REFERENCE 10: 135:55767

L20 ANSWER 61 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **115466-00-7** REGISTRY
CN Benzeneethanamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-.alpha.-methyl-2-(2-phenylethenyl)-, (E)-, (2E)-2-butenedioate (3:5) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneethanamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-.alpha.-methyl-2-(2-phenylethenyl)-, (E)-, (E)-2-butenedioate (3:5)

FS STEREOSEARCH
MF C28 H33 N O3 . 5/3 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 115198-40-8
CMF C28 H33 N O3

Double bond geometry as shown.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 109:54470

L20 ANSWER 62 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **115216-67-6** REGISTRY
CN Benzenepropanamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-N,.alpha.-dimethyl-2-(2-phenylethenyl)-, hydrochloride, (E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H37 N O3 . Cl H
SR CA
LC STN Files: CA, CAPLUS
CRN (115216-66-5)

Double bond geometry as shown.



● HCl

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 109:54470

L20 ANSWER 64 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **115198-55-5** REGISTRY
CN 1-Naphthaleneethanamine, N-[2-[2-[(2E)-2-(4-fluorophenyl)ethenyl]-5-methoxyphenyl]-1-methylethyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthaleneethanamine, N-[2-[2-[2-(4-fluorophenyl)ethenyl]-5-methoxyphenyl]-1-methylethyl]-, (E)-, (E)-2-butenedioate (2:1)
FS STEREOSEARCH
MF C30 H30 F N O . 1/2 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 115198-44-2
CMF C30 H30 F N O

Double bond geometry as shown.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 109:54470

L20 ANSWER 95 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **114799-60-9** REGISTRY
CN Benzoic acid, 2-[2-[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H25 Cl N2 O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

. 2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 112:191374

REFERENCE 2: 109:129008

L20 ANSWER 96 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **114787-47-2** REGISTRY
CN 1H-Imidazo[4,5-c]pyridine-6-carboxylic acid, 4,5,6,7-tetrahydro-5-(1-oxo-2,3-diphenyl-2-propenyl)-1-(phenylmethyl)-, [S-(E)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H25 N3 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 109:73432

L20 ANSWER 97 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **114773-12-5** REGISTRY
CN Benzonitrile, 2-[2-[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H24 Cl N3 O
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 112:191374

REFERENCE 2: 109:129008

L20 ANSWER 98 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **103545-15-9** REGISTRY
CN 2-Propanol, 1-(dimethylamino)-3-[4-(1,2-diphenyl-1-butenyl)phenoxy]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN ICI 94230

FS 3D CONCORD
MF C27 H31 N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:254532

REFERENCE 2: 107:109578

REFERENCE 3: 105:72884

L20 ANSWER 99 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **102106-41-2** REGISTRY
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2,3-diphenyl-2-propenyl methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C31 H28 N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 104:207168

L20 ANSWER 100 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **100982-50-1** REGISTRY
CN Piperazine, 1-(2,3-diphenyl-2-propenyl)-4-(3-pyridinylmethyl)- (9CI) (CA

INDEX NAME)
FS 3D CONCORD
MF C25 H27 N3
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 104:129927

L20 ANSWER 101 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **91221-46-4** REGISTRY
CN Phenol, 4,4'-(2-phenyl-1-butenylidene)bis- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H20 O2
CI COM
LC STN Files: BEILSTEIN*, CA, CANCERLIT, CAPLUS, CASREACT, DDFU, DRUGU, MEDLINE, TOXLIT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:254532

REFERENCE 2: 114:74630

REFERENCE 3: 108:198542

REFERENCE 4: 108:74905

REFERENCE 5: 107:146821

REFERENCE 6: 107:96423

REFERENCE 7: 106:116021

REFERENCE 8: 106:44227

REFERENCE 9: 101:72346

L20 ANSWER 102 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **82413-20-5** REGISTRY
CN Phenol, 3-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-,
(E)-
OTHER NAMES:
CN 3-Hydroxytamoxifen
CN Droloxifene
CN E-Droloxifene
CN K 060
CN K 060E
CN K 21.060E
FS STEREOSEARCH
MF C26 H29 N O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST,
CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE,
MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXLIT, ULIDAT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

171 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
171 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:267223

REFERENCE 2: 135:205530

REFERENCE 3: 135:132470

REFERENCE 4: 135:117261

REFERENCE 5: 135:76700

REFERENCE 6: 135:71241

REFERENCE 7: 135:14359

REFERENCE 8: 134:348291

REFERENCE 9: 134:305328

REFERENCE 10: 134:305076

L20 ANSWER 103 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **68684-63-9** REGISTRY
CN Phenol, 4-(1,2-diphenyl-1-butenyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-(1,2-Diphenylbut-1-enyl)phenol
CN ICI 77949
FS 3D CONCORD
MF C22 H20 O
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, DDFU, DRUGU, EMBASE, MEDLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1967 TO DATE)
12 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:282668

REFERENCE 2: 126:157285

REFERENCE 3: 125:292411

REFERENCE 4: 118:254532

REFERENCE 5: 112:69490

REFERENCE 6: 108:186248

REFERENCE 7: 103:17049

REFERENCE 8: 102:215475

REFERENCE 9: 102:672

REFERENCE 10: 99:641

L20 ANSWER 104 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **56287-31-1** REGISTRY
CN 1-Propanamine, 3-[4-[1-(4-methoxyphenyl)-2-nitro-2-phenylethenyl]phenoxy]-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN CI 680
MF C26 H28 N2 O4 . C6 H8 O7
LC STN Files: BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, DDFU, DRUGU, EMBASE, MEDLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 56287-30-0
CMF C26 H28 N2 O4



CM 2

CRN 77-92-9
CMF C6 H8 O7



15 REFERENCES IN FILE CA (1967 TO DATE)
15 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:86015

REFERENCE 2: 129:86008

REFERENCE 3: 129:67926

REFERENCE 4: 116:144146

REFERENCE 5: 113:561

REFERENCE 6: 105:72688

REFERENCE 7: 100:185961

REFERENCE 8: 100:96934

REFERENCE 9: 97:1031

REFERENCE 10: 96:80182

L20 ANSWER 105 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **54965-24-1** REGISTRY
CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
OTHER NAMES:
CN ICI 46474
CN Nolvadex
CN Tamoplex
CN Tamox-Puren
CN Tamoxifen citrate
CN Z-Tamoxifen citrate
FS STEREOSEARCH
MF C26 H29 N O . C6 H8 O7
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DIOGENES, DRUGPAT, EMBASE, HSDB*, IPA, MRCK*, MSDS-OHS, PHARMASEARCH, PIRA, PROMT, RTECS*, TOXLIT, ULIDAT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 10540-29-1
CMF C26 H29 N O

Double bond geometry as shown.



CM 2

CRN 77-92-9
CMF C6 H8 O7



180 REFERENCES IN FILE CA (1967 TO DATE)
180 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:252083

REFERENCE 2: 135:205083

REFERENCE 3: 135:174425

REFERENCE 4: 135:71266

REFERENCE 5: 134:371761

REFERENCE 6: 134:173196

REFERENCE 7: 134:66360

REFERENCE 8: 134:32972

REFERENCE 9: 133:359224

REFERENCE 10: 133:340231

L20 ANSWER 106 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **53005-05-3** REGISTRY
CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-isothiocyanato- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4,4'-Diisothiocyanato-2,2'-stilbenedisulfonic acid
CN DIDS
FS 3D CONCORD
MF C16 H10 N2 O6 S4
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IPA, MEDLINE, NIOSHTIC, PIRA,

TOXLIT, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

527 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
527 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:314438

REFERENCE 2: 135:301293

REFERENCE 3: 135:299709

REFERENCE 4: 135:298460

REFERENCE 5: 135:298121

REFERENCE 6: 135:271097

REFERENCE 7: 135:237995

REFERENCE 8: 135:207895

REFERENCE 9: 135:118359

REFERENCE 10: 135:102474

L20 ANSWER 107 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **51023-76-8** REGISTRY
CN Benzenesulfonic acid, 5-(acetylamino)-2-[2-(4-isothiocyanato-2-sulfophenyl)ethenyl]-, disodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Disodium 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonate
CN SITS
MF C17 H14 N2 O7 S3 . 2 Na
LC STN Files: ADISINSIGHT, AGRICOLA, BIOBUSINESS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, MSDS-OHS, TOXLIT, USPATFULL
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (27816-59-7)



●2 Na

146 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
146 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:314438

REFERENCE 2: 135:298460

REFERENCE 3: 135:31877

REFERENCE 4: 134:110420

REFERENCE 5: 133:218637

REFERENCE 6: 133:114784

REFERENCE 7: 133:13989

REFERENCE 8: 133:12415

REFERENCE 9: 132:305946

REFERENCE 10: 131:297859

L20 ANSWER 108 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **15690-57-0** REGISTRY
CN Ethanamine, 2-[4-[(1E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-, (E)-
CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]-, (E)- (8CI)
OTHER NAMES:
CN (E)-Clomiphene
CN 2-[p-(2-Chloro-trans-1,2-diphenylvinyl)phenoxy]triethylamine
CN Enclomifene
CN Enclomiphene
CN ICI 46476
CN trans-Clomifene
CN trans-Clomiphene
FS STEREOSEARCH
DR 96189-16-1
MF C26 H28 Cl N O
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMINFORMRX, CHEMLIST, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, RTECS*, TOXCENTER, TOXLIT, USAN, USPATFULL, VETU

(*File contains numerically searchable property data)
Other Sources: WHO

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

123 REFERENCES IN FILE CA (1967 TO DATE)
123 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:134953

REFERENCE 2: 134:320982

REFERENCE 3: 134:285588

REFERENCE 4: 134:271284

REFERENCE 5: 131:281723

REFERENCE 6: 131:252109

REFERENCE 7: 130:105686

REFERENCE 8: 130:20130

REFERENCE 9: 129:339850

REFERENCE 10: 129:326941

L20 ANSWER 110 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **10540-29-1** REGISTRY
CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-
CN Ethylamine, 2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- (8CI)
OTHER NAMES:
CN ICI 47699
CN Mammaton
CN Tamofen
CN Tamoxifen
CN trans-Tamoxifen
CN Z-Tamoxifen
FS STEREOSEARCH
MF C26 H29 N O

CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, EMBASE, HSDB*, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER, TOXLIT, ULIDAT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4094 REFERENCES IN FILE CA (1967 TO DATE)
118 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4108 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:316401

REFERENCE 2: 135:313756

REFERENCE 3: 135:313606

REFERENCE 4: 135:313519

REFERENCE 5: 135:313320

REFERENCE 6: 135:313271

REFERENCE 7: 135:313025

REFERENCE 8: 135:302906

REFERENCE 9: 135:300662

REFERENCE 10: 135:298909

L20 ANSWER 111 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **10448-84-7** REGISTRY
CN Pyrrolidine, 1-[2-[4-[1-(4-methoxyphenyl)-2-nitro-2-phenylethenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyrrolidine, 1-[2-[p-[.alpha.-(p-methoxyphenyl)-.beta.-nitrostyryl]phenoxy]ethyl]- (7CI, 8CI)
OTHER NAMES:

CN CN 55945
CN Nitromifene
FS 3D CONCORD
DR 35258-22-1
MF C27 H28 N2 O4
CI COM
LC STN Files: BEILSTEIN*, CA, CANCERLIT, CAOLD, CAPLUS, DDFU, DRUGU, MEDLINE, RTECS*, TOXCENTER, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

25 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
25 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:25113

REFERENCE 2: 132:217295

REFERENCE 3: 132:156868

REFERENCE 4: 130:148713

REFERENCE 5: 122:305842

REFERENCE 6: 114:17699

REFERENCE 7: 113:561

REFERENCE 8: 112:30764

REFERENCE 9: 110:3209

REFERENCE 10: 108:49540

L20 ANSWER 112 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **5863-35-4** REGISTRY
CN Pyrrolidine, 1-[2-[4-[1-(4-methoxyphenyl)-2-nitro-2-phenylethenyl]phenoxy]ethyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyrrolidine, 1-[2-[p-[.alpha.-(p-methoxyphenyl)-.beta.-nitrostyryl]phenoxy]ethyl]-, citrate (7CI)
CN Pyrrolidine, 1-[2-[p-[.alpha.-(p-methoxyphenyl)-.beta.-nitrostyryl]phenoxy]ethyl]-, citrate (1:1) (8CI)
OTHER NAMES:
CN 1-[2-(p-[a-(p-Methoxyphenyl)-.beta.-nitrostyryl]-phenoxy)ethyl]pyrrolidine monocitrate
CN 1-[2-[4-[2-(4-Methoxyphenyl)-1-nitro-2-phenylethenyl]phenoxy]ethyl]pyrrolidine monocitrate
CN 1-[2-[p-[.alpha.-(p-Methoxyphenyl)-.beta.-nitrostyryl]phenoxy]ethyl]pyrrolidine monocitrate
CN 1-[2-[p-[.alpha.-(p-Methoxyphenyl)-.beta.-nitrostyryl]phenoxy]ethyl]pyrrolidine monocitrate
CN CI 628
CN CN 55945-27
CN Nitromifene citrate
CN Parke Davis CI-628
DR 11126-33-3, 28794-69-6
MF C27 H28 N2 O4 . C6 H8 O7
LC STN Files: BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, EMBASE, RTECS*, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 10448-84-7
CMF C27 H28 N2 O4

[redacted]



CM 2

CRN 77-92-9
CMF C6 H8 O7



190 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
190 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:29254

REFERENCE 2: 130:320985

REFERENCE 3: 129:86015

REFERENCE 4: 129:86008

REFERENCE 5: 129:67926

REFERENCE 6: 128:176274

REFERENCE 7: 126:195078

REFERENCE 8: 119:109266

REFERENCE 9: 116:853

REFERENCE 10: 115:174956

L20 ANSWER 113 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **911-45-5** REGISTRY
CN Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]- (7CI, 8CI)
OTHER NAMES:
CN 1-(p-.beta.-Diethylaminoethoxyphenyl)-1,2-diphenyl-2-chloroethylene
CN 2-[p-(.beta.-Chloro-.alpha.-phenylstyryl)phenoxy]triethylamine
CN 2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine
CN Clomifene
CN Clomiphene
CN Clomiphene B
FS 3D CONCORD
MF C26 H28 Cl N O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PROMT, RTECS*, SPECINFO, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

501 REFERENCES IN FILE CA (1967 TO DATE)
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
501 REFERENCES IN FILE CAPLUS (1967 TO DATE)
16 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:253084

REFERENCE 2: 135:231505

REFERENCE 3: 135:216008

REFERENCE 4: 135:175656

REFERENCE 5: 135:149615

REFERENCE 6: 135:132406

REFERENCE 7: 135:132352

REFERENCE 8: 135:117331

REFERENCE 9: 135:116519

REFERENCE 10: 135:102687

L20 ANSWER 114 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **569-57-3** REGISTRY
CN Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris[4-methoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Chlorotrianisene (6CI)
CN Ethylene, chlorotris(p-methoxyphenyl)- (7CI, 8CI)
OTHER NAMES:
CN Anisene
CN Chlorotris(p-methoxyphenyl)ethylene
CN Chlortrianizen
CN Clorestrolo
CN Clorotrisin
CN Hormonisene
CN Khlortrianizen
CN Merbentul
CN Metace
CN NSC 10108
CN Rianil
CN Tace
CN Tace (pharmaceutical)
CN Tri-p-anisylchloroethylene
CN Trianisylchloroethylene
CN Tris(p-methoxyphenyl)chloroethylene
FS 3D CONCORD
DR 13003-83-3
MF C23 H21 Cl O3
LC STN Files: ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IPA, MEDLINE, MRCK*, NIOSHTIC, PROMT, RTECS*, SPECINFO, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

101 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
101 REFERENCES IN FILE CAPLUS (1967 TO DATE)
30 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:288636

REFERENCE 2: 135:190550

REFERENCE 3: 135:127211

REFERENCE 4: 134:33012

REFERENCE 5: 133:305586

REFERENCE 6: 133:217722

REFERENCE 7: 133:129857

REFERENCE 8: 133:109949

REFERENCE 9: 132:329551

REFERENCE 10: 132:156865

L20 ANSWER 115 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **522-40-7** REGISTRY
CN Phenol, 4,4'-[(1E)-1,2-diethyl-1,2-ethenediyl]bis-, bis(dihydrogen phosphate) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4,4'-Stilbenediol, .alpha.,.alpha.'-diethyl-, bis(dihydrogen phosphate), (E)- (8CI)
CN Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, bis(dihydrogen phosphate), (E)-
OTHER NAMES:
CN .alpha.,.alpha.'-Diethyl-4,4'-stilbenediol diphosphoric acid ester
CN Diethyldihydroxystilbene diphosphate
CN Diethylstilbesterol diphosphate
CN Diethylstilbestrol diphosphate
CN Diethylstilbestryl diphosphate
CN Fosfestrol
CN Honvan
CN Phosphestrol
CN ST 52-Asta
CN Stilbestrol diphosphate
CN Stilphostrol
FS STEREOSEARCH
DR 43049-99-6
MF C18 H22 O8 P2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMLIST, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IPA, MRCK*, NIOSHTIC, PHARMASEARCH, PROMT, RTECS*, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

138 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
138 REFERENCES IN FILE CAPLUS (1967 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:33012

REFERENCE 2: 132:73826

REFERENCE 3: 131:346535

REFERENCE 4: 131:194509

REFERENCE 5: 131:156287

REFERENCE 6: 131:35892

REFERENCE 7: 131:23554

REFERENCE 8: 131:23553

REFERENCE 9: 130:108397

REFERENCE 10: 130:482

L20 ANSWER 116 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **495-99-8** REGISTRY
CN Benzenecarboximidamide, 4-[2-[4-(aminoiminomethyl)phenyl]ethenyl]-3-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4,4'-Stilbenedicarboxamidine, 2-hydroxy- (7CI, 8CI)
OTHER NAMES:
CN 2-Hydroxy-4,4'-stilbenedicarboxamidine
CN Hydroxystilbamidine
CN OHSA
FS 3D CONCORD
MF C16 H16 N4 O
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CEN, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, MEDLINE, MRCK*, PIRA, RTECS*, SPECINFO, TOXLIT, USAN, USPATFULL

(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

41 REFERENCES IN FILE CA (1967 TO DATE)
41 REFERENCES IN FILE CAPLUS (1967 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:24675

REFERENCE 2: 135:114

REFERENCE 3: 132:339430

REFERENCE 4: 124:44887

REFERENCE 5: 116:37120

REFERENCE 6: 115:227445

REFERENCE 7: 110:162889

REFERENCE 8: 105:205223

REFERENCE 9: 105:17878

REFERENCE 10: 104:141770

L20 ANSWER 117 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **316-23-4** REGISTRY
CN Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, bis(hydrogen sulfate), (E)-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4,4'-Stilbenediol, .alpha.,.alpha.'-diethyl-, bis(hydrogen sulfate), (E)-
(8CI)
OTHER NAMES:
CN .alpha.,.alpha.'-Diethyl-4,4'-stilbenediol disulfuric acid ester, (E)-
CN Diethylstilbestrol 4,4'-disulfuric ester
CN Diethylstilbestrol disulfate
CN Diethylstilbestryl disulfate
CN Stilbestrol disulfate
FS STEREOSEARCH
MF C18 H20 O8 S2
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CHEMLIST, TOXLIT
(*File contains numerically searchable property data)
Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 90:16821

REFERENCE 2: 83:126645

REFERENCE 3: 79:122020

REFERENCE 4: 76:81403

REFERENCE 5: 72:392

REFERENCE 6: 70:84604

REFERENCE 7: 70:17363

L20 ANSWER 118 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **56-53-1** REGISTRY
CN Phenol, 4,4'-[(1E)-1,2-diethyl-1,2-ethenediyl]bis- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 4,4'-Stilbenediol, .alpha.,.alpha.'-diethyl-, (E)- (8CI)
CN Phenol, 4,4'-(1,2-diethyl-1,2-ethenediyl)bis-, (E)-
OTHER NAMES:
CN (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene
CN (E)-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol
CN (E)-Diethylstilbestrol
CN .alpha.,.alpha.'-Diethyl-4,4'-stilbenediol
CN .alpha.,.alpha.'-Diethylstilbenediol
CN 4,4'-Dihydroxy-.alpha.,.beta.-diethylstilbene
CN 4,4'-Dihydroxydiethylstilbene
CN Agostilben
CN Antigestil
CN Bio-des
CN Bufon
CN Comestrol
CN Cyren
CN Cyren A
CN Dawe's destrol
CN DEB
CN DES
CN DES (synthetic estrogen)

CN Di-Estryl
CN DiBestrol 2 Premix
CN Diethylstilbestrol
CN Distilbene
CN Domestrol
CN Estilbin MCO
CN Estrobene
CN Estromenin
CN Estrosyn
CN Fonatol
CN Grafestrol
CN Hi-Bestrol
CN Iscovesco
CN Menostilbeen
CN Microest
CN Milestrol
CN Neo-Oestranol I
CN Oestrogenine
CN Oestromenin
CN Oestromensyl
CN Pabestrol
CN Palestrol
CN Rumestrol 1
CN Rumestrol 2
CN Serral
CN Sexocretin
CN Sibol
CN Stil
CN Stil-Rol
CN Stilbestrol
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS STEREOSEARCH
DR 8026-45-7, 8028-09-9, 8030-34-0, 8049-42-1, 8053-00-7
MF C18 H20 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLIT, ULIDAT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4816 REFERENCES IN FILE CA (1967 TO DATE)
91 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4821 REFERENCES IN FILE CAPLUS (1967 TO DATE)
35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:314622

REFERENCE 2: 135:313797

REFERENCE 3: 135:313320

REFERENCE 4: 135:303215

REFERENCE 5: 135:299875

REFERENCE 6: 135:288636

REFERENCE 7: 135:288504

REFERENCE 8: 135:286909

REFERENCE 9: 135:284382

REFERENCE 10: 135:284251

L20 ANSWER 119 OF 119 REGISTRY COPYRIGHT 2001 ACS
RN **50-41-9** REGISTRY
CN Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]-, citrate (6CI, 7CI)
CN Triethylamine, 2-[p-(2-chloro-1,2-diphenylvinyl)phenoxy]-, citrate (1:1) (8CI)
OTHER NAMES:
CN 1-[p-(.beta.-Diethylaminoethoxy)phenyl]-1,2-diphenyl-2-chloroethylene citrate
CN 2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine dihydrogen citrate
CN Chloramiphene
CN Clomid
CN Clomifene citrate
CN Clomifeno
CN Clomiphene citrate
CN Clomiphene dihydrogen citrate
CN Clomivid
CN Clomphid
CN Clostilbegyt
CN Dyneric
CN Fertivet
CN Fertyl
CN Genozym
CN Ikaclomin
CN Mer 41
CN MRL 41
CN Omifin
CN Racemic clomiphene citrate
MF C26 H28 Cl N O . C6 H8 O7

CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DIOGENES, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, NIOSHTIC, PHARMASEARCH, PROMT, RTECS*, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 911-45-5
CMF C26 H28 Cl N O



CM 2

CRN 77-92-9
CMF C6 H8 O7



644 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
646 REFERENCES IN FILE CAPLUS (1967 TO DATE)
25 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:268418

REFERENCE 2: 135:267389

REFERENCE 3: 135:221503

REFERENCE 4: 135:221432

REFERENCE 5: 135:221411

REFERENCE 6: 135:205651

REFERENCE 7: 135:116199

REFERENCE 8: 135:71383

[redacted]

REFERENCE 9: 134:290552

REFERENCE 10: 134:285588